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1CHAPTER I
INTRODUCTION
Almost thirty years ago, p53 was identified as a simian virus 40 (SV40)
large T antigen interacting protein.  The 53 kDa protein was immunoprecipitated
from SV40-transformed mouse cell lysates using anti-large T serum isolated from
rabbits, hamsters, mice, and monkeys (Lane and Crawford, 1979).  In addition to
SV40-transformed mouse cells, p53 could also be immunoprecipitated from
uninfected mouse embryonal carcinoma cells in the absence of large T (Linzer
and Levine, 1979).  Using anti-large T serum, p53 could be immunopurified from
any transformed cell examined.  The presence of p53 distinguished sarcomas
from normal cells (DeLeo et al., 1979).  Furthermore, p53 could be
immunoprecipitated out of many different SV40-transformed cell lysates by anti-
large T sera isolated from several distinct species (Kress et al., 1979; Chang et
al., 1979).  Of note, in these early experiments, p53 was determined to be a
phosphoprotein (Linzer and Levine, 1979; Kress et al., 1979; Chang et al., 1979).
Analogous to the interaction of p53 with SV40 large T antigen, the interaction of
p53 with another viral protein important for transformation, adenovirus E1B, was
reported (Sarnow et al., 1982).  The interaction of p53 with multiple viral proteins
was of interest as understanding transformation by DNA tumor viruses was
sought.
2Another observation made in early studies on p53 was that high levels of
p53 were expressed in cancer cells, whereas levels of p53 in non-transformed
cells were low (DeLeo et al., 1979; Rotter et al., 1980).  Furthermore, p53
cooperated with activated ras in the transformation of primary embryonic cell
cultures into tumorigenic cells (Eliyahu et al., 1984; Parada et al., 1984).
Consequently, p53 was initially thought to be an oncogene.  However, upon
determination of the sequence of wild-type p53, comparison of the p53 protein
exhibiting oncogenic properties revealed an alanine to valine mutation at amino
acid 135 (A135V).  Unlike the A135V mutant, the wild-type p53 protein was not
able to cooperate with ras to transform cells (Hinds et al., 1989).  Further studies
demonstrated that wild-type p53 was actually a suppressor of transformation
(Baker et al., 1989; Finlay et al., 1989).  Soon thereafter, p53 was shown to
interact with human papilloma virus 16 (HPV-16) E6 protein (Werness et al.,
1993) and that the functional consequence of this interaction is ubiquitin-
mediated degradation of p53 by the proteasome (Scheffner et al., 1990).  That
multiple DNA tumor viruses target p53 in order to allow for transformation and
progression of cancer is indicative of how critical intact p53 signaling pathways
are in preventing uncontrolled cell growth.  This chapter will review the current
understanding of the roles of p53 structure and function and target gene
regulation.
3p53 Alterations in Cancer
Mutations in p53 are the most common genetic alteration in human
cancer.  Approximately 50% of all human tumors contain p53 mutations
(Vogelstein, 1990).  Deletions in chromosome 17p are common in many types of
tumors, including colorectal tumors.  Studies on colorectal tumors determined
that the “target” of the 17p deletion is the p53 gene (Baker et al., 1989).  When
17p is not deleted, mutations in p53 are frequently detected (Baker et al., 1989;
Nigro et al., 1989).  The most common p53 mutations found in human tumors are
clustered in four “hot spots” that overlap with the most conserved regions of the
p53 gene (Nigro et al., 1989).  The most highly conserved regions are located in
the central region of the p53 protein, which contains the DNA binding domain
(Pavletich et al., 1993).  The crystal structure of the p53 core domain in complex
with DNA provides a structural explanation regarding the nature of many
mutations in p53 found in human tumors (Cho et al., 1994).  The six most
frequent p53 codons mutated in cancer are arginine (R) 248, R273, R175,
glycine (G) 245, R249, and R282 (Hollstein et al., 1991).  The crystal structure
illustrates that R248 and R273 are both in direct contact with DNA (Cho et al.,
1994).  R175, G245, R249, and R282 are all residues critical for maintaining
structural integrity of the p53 protein.  Each of these four amino acids is essential
for proper conformation, folding, hydrogen bonding, salt bridge interactions, and
packing of the core domain of p53 (Cho et al., 1994).
4The role of p53 in tumor suppression was also confirmed from the
phenotype of the p53 knock-out mouse and humans with germ-line mutations in
the gene.  Mice lacking p53 develop and are born normally for the most part.
However, spontaneous tumors, most commonly lymphomas and sarcomas, form
in the p53 knock-out mouse before they are 6 months old (Donehower et al.,
1992).  Germ-line mutations in the p53 gene are found in people affected with Li-
Fraumeni syndrome (LFS) (Malkin et al., 1990; Srivastava et al., 1990).  LFS
results from an inherited point mutation in a conserved region of p53 that results
in cancer susceptibility in affected people.  A wide range of childhood and adult
cancers are observed in people with LFS (Malkin et al., 1990; Srivastava et al.,
1990).  The high frequency of mutations and deletions of the p53 gene in human
tumors illustrates the integral role of p53 in tumor suppression.
p53 Protein Structure and Interacting Proteins
The p53 protein is comprised of 393 amino acids that account for a
molecular mass of 53,000 daltons.  p53 structurally consists of three functional
domains: a transactivation domain (TAD), a DNA binding domain (DBD), and an
oligomerization domain.  Each domain is involved in processes important to p53
regulation and function.
5p53 N-terminus
The first 73 N-terminal amino acids of p53 contain the acidic TAD (Fields
and Jang, 1990).  The TAD is also the site where many interacting proteins bind
to p53.  Important to the ability of p53 to activate transcription, components of the
transcription initiation factor IID (TFIID) associate with the N-terminus of p53.
Specifically, TATA box binding protein (TBP) (Seto et al., 1992) and TBP-
associated factors (TAFs) TAFII32 and TAFII70 interact with the N-terminus of
p53 (Lu and Levine, 1995; Thut et al., 1995).  In addition, cAMP response
element-binding protein (CREB)-binding protein (CBP)/p300 complex is known to
interact with p53 at its N-terminus. CBP/p300 serves as a transcriptional
coactivator and potentiates p53-mediated transcription (Gu et all, 1997; Lill et al.,
1997; Avantaggiati et al., 1997).  CBP/p300 has histone acetyltransferase (HAT)
activity and is able to acetylate histones in regions of transcriptionally active
chromatin (Bannister and Kouzarides, 1996; Ogryzko et al., 1996).  CBP/p300
also acetylates the p53 C-terminus, which enhances its sequence specific
binding ability (Gu and Roeder, 1997).  The adenovirus E1b protein binds to p53
at its N-terminus and inhibits transcriptional activation (Kao et al., 1990).  One of
the most important p53 interacting proteins binds to p53 at the N-terminus:
MDM2 (Oliner et al., 1993).  MDM2 negatively regulates p53 by associating with
the TAD and inhibiting p53 transactivation (Oliner et al., 1993) and also targets
p53 for ubiquitination and rapid degradation by the 26S proteasome (Haupt et al.,
1997; Kubbutat et al., 1998).  A region of the p53 protein near the N-terminus
6and adjacent to the TAD is referred to as the proline-rich domain, which consist
of amino acids 61-94 and contains five repeats of the sequence PXXP, where P
= proline, and X = any amino acid (Walker and Levine, 1996).  The proline-rich
region of p53 was found to be important for the ability of p53 to induce apoptosis
(Sakamoro et al., 1997).  A common polymorphism of p53, either P or R at amino
acid 72, is located in the proline-rich region (Matlashewski et al., 1987).  There
are differences in the functioning of the p53 protein depending on which
polymorphism is encoded. The p53 protein with R72 is able to induce apoptosis
better than p53 with P72 (Dumont et al., 2003), whereas the presence of P72
renders p53 able to induce increased levels of G1 arrest than p53 with R72 (Pim
and Banks, 2004).  The processes involving the p53 N-terminus demonstrate the
importance of its role in p53-mediated transcription.
p53 Central Core
Another important functional domain of p53 is the DBD, located in the
central region of the p53 protein (amino acids 102-292).  As mentioned earlier,
the DBD contains four conserved regions that are mutational “hot-spots” in
human cancers (Pavletich et al., 1993).  In 1991, p53 was found to have the
ability to bind to DNA in a sequence-specific manner (Kern et al., 1991).  Soon
thereafter, the same group defined the sequence of the p53 consensus binding
site to be 2 repeats of RRRC(A/T)(T/A)GYYY (R = A or G, Y = C or T) separated
by 0-13 basepairs of random sequence (El-Deiry et al., 1992).  The sequence of
7the p53 binding site is highly degenerate in the p53 target genes identified to
date.  p53 was then shown to directly activate transcription through this
consensus binding site (Farmer et al., 1992).  Later studies proved that p53
requires this sequence-specific transcriptional activity to function as a tumor
suppressor (Pietenpol et al., 1994).  As with the N-terminus, proteins that interact
with the DBD of p53 can affect the function of p53.  The SV40 large T antigen
binds to the DBD of p53 to inhibit its function (Tan et al., 1986).  The HPV E6
protein also binds to the core domain of p53 to promote its degradation (Li and
Coffino, 1996).  Two additional cofactors, p53 binding protein 1 (53BP1) and p53
binding protein 2 (53BP2), also interact with the p53 DBD (Iwabuchi et al., 1994;
Gorina and Pavletich, 1996).  53BP1 and 2 have the ability to act as
transcriptional cofactors and enhance p53 transactivation (Iwabuchi et al, 1998).
Also, heat shock cognate protein 70 (hsc70) binds to the DBD of p53 mutant
proteins containing mutations in residues such as R175 and V143 that alter the
structure of the protein (Fourie et al., 1997; Hinds et al., 1990).  Such properties
of the p53 DBD illustrate its essential role in p53-mediated signaling.
p53 C-terminus
The C-terminus of p53, amino acids 300-393, is also important for several
aspects of p53 function and regulation.  Amino acids 300-318 constitute a flexible
linker region that connects the central core and the C-terminus of p53 (Cho et al.,
1994).  The oligomerization domain consists of amino acids 323-355.  When
8binding to DNA, p53 oligomerizes to form tetramers by means of the
oligomerization domain (Wang et al., 1994).  Tetramerization is necessary for
p53 to proficiently transactivate targets and suppress growth of cancer cell lines
(Pietenpol et al., 1994).  The C-terminus of p53 also contains three nuclear
localization signals (NLS) in amino acids 316-325, 369-375, and 379-384.  The
NLS in amino acids 316-325 contains the greatest nuclear localization ability.
Correspondingly, this NLS is also conserved in several species and the
sequence best matches the consensus sequence of a typical NLS (Dang and
Lee, 1989; Shaulsky et al, 1990).  Stommel et al. (1999) identified a nuclear
export signal (NES) in the C-terminus of p53, located specifically within the
oligomerization domain.  They proposed that when p53 tetramerizes and binds
DNA, the NES is concealed, preventing p53 export from the nucleus (Stommel et
al., 1999).  Finally, amino acids 363-393 of the p53 C-terminus constitute a basic
domain has the ability to negatively regulate p53 sequence-specific DNA binding.
Deletion of the C-terminal domain or binding of the p53 monoclonal antibody
PAb421 to the p53 C-terminus counteracts the negative regulation and activates
sequence-specific binding.  The PAb421 antibody relieves the allosteric inhibition
of DNA binding by inducing a conformational change in the protein (Hupp and
Lane, 1994).  Post-translational modifications in this basic domain in the C-
terminus domain also activate sequence-specific DNA binding (Hupp et al., 1992;
Hupp et al., 1993; Hupp and Lane, 1994).  In summary, the C-terminus of p53 is
also involved in several important aspects of p53 function.
9p53 Post-translational Modifications
During conditions of basal cellular functioning, p53 protein levels are very
low due to its short half-life (Maltzman and Czyzyk, 1984) and rapid turnover
mediated through its interaction with MDM2, as mentioned above.  However,
when cells encounter genotoxic stress, the p53 protein is activated as a result of
many different types of post-translational modifications (Appella and Anderson,
2001).
Phosphorylation
Phosphorylation is one of the most important modifications of p53 and
increases its sequence-specific binding ability (Hupp and Lane, 1994).  In the N-
terminus of p53, serines (S) 6, 9, 15, 20, 33, 37, and 46 and threonines (T) 18
and 81 are phosphorylated in response to genotoxic stress.  The phosphorylation
of S15 is well-studied and important for several reasons.  Phosphorylation of S15
on the N-terminus of p53 contributes to the disruption of the p53/MDM2 complex
resulting in the stabilization of p53 protein (Shieh et al., 1997). Of note, post-
translational modification of MDM2 also contributes to disruption of the
p53/MDM2 complex (Brooks and Gu, 2003).  Zhang and Xiong (2001) reported
the presence of another NES in p53 consisting of amino acids 11-27 in the N-
terminus.  Upon the phosphorylation of S15 within this region, p53 is no longer
exported from the nucleus (Zhang and Xiong, 2001).  Phosphorylation of p53 at
S15 increases the ability of p53 to bind to p300/CBP, and the subsequent
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acetylation at the C-terminus of p53 (Lambert et al., 1998).  Overall, S15
phosphorylation of p53 results in enhanced transcriptional activation ability,
which is exemplified by the aforementioned properties.
Phosphorylation events that occur in the p53 C-terminal basic domain also
have implications in the regulation of p53 activity.  p53 is phosphorylated at
S315, S376, S371, S378, and S392 in its C-terminal domain.  Casein kinase 2
(CK2) is able to phosphorylation S392 in the C-terminus of p53 (Keller et al.,
2001).  In addition, protein kinase C (PKC) phosphorylates S371, S376, and
S378 in the basic domain in the C-terminus (Takenaka et al., 1995).
Phosphorylation of these serines in the C-terminal basic domain stabilizes p53
tetramerization and activates sequence-specific DNA binding (Hupp et al., 1992;
Hupp et al., 1993; Hupp and Lane, 1994).
Many different protein kinases have been implicated in phosphorylating
specific serines and threonines in the p53 protein.  Examples include ataxia
telangiectasia mutated (ATM), ATM- and Rad3-related (ATR), checkpoint
kinases 1 and 2 (Chk1, Chk2), c-jun N-terminal kinase (JNK), casein kinase 1
and 2 (CK1, CK2), protein kinase C (PKC), p38 stress activated kinase, and
DNA-dependent protein kinase (DNAPK) (Bode and Dong, 2004).  Some kinases
are able to phosphorylate more than one site in p53, and some sites can be
phosphorylated by more than one kinase.  In general, the sites in p53 that are
phosphorylated in response to a genotoxic stress are dependent on which kinase
is activated by that particular stress.  In addition, the particular kinase that gets
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activated depends on the type and extent of the stress and the sort of cellular
outcome that needs to occur to deal with that stress (i.e. cell cycle arrest vs.
apoptosis) (Bode and Dong, 2004).  In summary, though the mechanistic details
of phosphorylation of the p53 protein are numerous and convoluted, this type of
post-translational modification plays an important role in the p53-mediated
response to genotoxic stress.
Acetylation
Other post-translational modifications of p53 include acetylation,
ubiquitination, sumoylation, neddylation, and methylation.  These modifications
occur at lysine residues in the C-terminal domain of p53.  p300/CBP acetylates
p53 at lysines (K) 370, 372, 373, 381, and 382.  These five lysine residues are
highly conserved (Gu and Roeder, 1997).  K320 is acetylated by p300/CBP-
associated factor (PCAF) (Liu et al., 1999).  Acetylation of these lysines in the C-
terminus of p53 occurs in response to DNA damage.  Like phosphorylation,
acetylation of the C-terminal basic domain results in an increase in p53
sequence-specific binding ability in both in vitro binding assays and at the p21
promoter in human lung carcinoma H460 cells using chromatin
immunoprecipitation (ChIP) (Gu and Roeder, 1997; Luo et al., 2004).  In addition,
there is coordination of the phosphorylation and acetylation of p53 in response to
DNA damage.  Phosphorylation at S15 happens first, stabilizing p53 and allowing
for phosphorylation at other serines (Lambert et al., 1998).  Also, p300/CBP has
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higher affinity for p53 phosphorylated at S15 (Lambert et al., 1998).  Following
association with p53, p300/CBP acetylates lysines in the C-terminal domain,
resulting in upregulation of sequence-specific binding of p53 to DNA (Sakaguchi
et al., 1998).  Interplay between phosphorylation and acetylation modifications
results in a rapid response to DNA damage.
Ubiquitination
Another post-translational modification of p53 important to its regulation
and function is ubiquitination.  In unstressed cells, p53 protein levels are kept low
through modulation by the ubiquitin-proteasome system.  MDM2, an important
negative regulator of p53, is the E3-ubiquitin ligase in the pathway to the
degradation of p53 (Honda et al., 1997).  In addition to targeting p53 for
degradation, MDM2 also inhibits the transcriptional activity of p53 by binding to
its N-terminal TAD (Oliner et al., 1993), as mentioned earlier.  Mutational analysis
on the C-terminal domain of p53 revealed six lysine residues ubiquitinated by
MDM2: K370, K372, K373, K381, K382, and K386.  Mutating all six of these
lysine residues to arginines renders p53 resistant to MDM2-mediated
degradation (Rodriguez et al., 2000).  Ubiquitination of p53 was shown to be a
reversible process from the identification of herpes virus-associated ubiquitin-
specific protease (HAUSP).  HAUSP binds to p53, deubiquitinates it, resulting in
p53 protein stabilization (Li et al., 2002).  Further studies in which expression of
HAUSP is knocked-down using RNAi revealed that HAUSP is required for the
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stability of MDM2 during basal cell activity.  Therefore, when expression of
HAUSP was almost completely eliminated, p53 was stabilized and activated
(Cummins et al., 2004; Li et al., 2004).  The function of a HAUSP regulatory
pathway maintaining the balance between MDM2 and p53 levels is another level
of protection against tumorigenesis.
Sumoylation
Sumoylation and neddylation are covalent post-translational modifications
that resemble ubiquitination.  Sumoylation involves the addition of a small
ubiquitin-related modifier (SUMO-1) through a pathway similar to that of the
ubiquitin-conjugation process.  Sumoylated-p53 accumulates in response to
ultraviolet radiation (UV).  The SUMO-1 modification is specifically conjugated to
p53 at K386 (Rodriguez et al., 1999; Gostissa et al., 1999).  Unlike ubiquitination,
sumoylation of p53 does not lead to p53 protein degradation.  Rather, the
presence of this modification in the basic C-terminal domain of p53 results in an
increase in p53 sequence-specific binding (Rodriguez et al., 1999; Gostissa et
al., 1999), as is the case with phosphorylation and acetylation.
Neddylation
NEDD8 is another ubiquitin-like covalent modification and is the most
homologous to ubiquitin out of all ubiquitin-like proteins.  Neddylation (the
addition of NEDD8) also occurs through a pathway similar to ubiquitin-
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conjugation.  MDM2 can function as an “E3 NEDD8 ligase” and neddylate p53 on
K370, K372, and K373 of the basic C-terminal domain (Xirodimas et al., 2004).
Of note, these three lysines are also sites that can be ubiquitinated as mentioned
above.  MDM2 also neddylates itself, just as it is able to self-ubiquitinate.  The
result of neddylation of p53 and MDM2 is that both proteins are inactivated.  In
this way, neddylation serves to negatively regulate both p53 and MDM2
(Xirodimas et al., 2004).  Neddylation of p53 and MDM2 is another way in which
the balance in expression of each protein is carefully controlled.
Methylation
Chuikov et al. (2004) demonstrated the first example of methylation as a
post-transcriptional modification of p53.  Set9, a histone methyltransferase, can
methylate K372 in the basic C-terminal domain of p53.  A Set9 consensus
binding motif was identified by comparing the sites of methylation in histones and
p53.  Methylation of p53 is observed both in vitro and by immunoprecipitation of
endogenous p53 from cells (Chuikov et al., 2004).  An increase in methylated
p53 can be detected in cells treated with adriamycin (ADR).  As observed with
phosphorylation, acetylation, and sumoylation, methylation at K372 in the C-
terminus of p53 results in an increase in p53 transcriptional activity.  In addition,
overexpression of Set9 in U2OS cells results in increased apoptosis, both basally
and following ADR treatment  (Chuikov et al., 2004).  Interestingly, K372 can be
acetylated, ubiquitinated, neddylated, and methylated as determined by these
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studies of post-translational modifications of p53.  This is another illustration of
the complexities of post-translational modifications.  Therein lies the potential for
distinct cellular outcomes mediated by differential regulation of the many post-
transcriptional modifications of p53.
Transcriptional Regulation of Target Genes by p53
In response to cellular stress, p53 regulates a complex signal transduction
pathway of genes and proteins that results in a cellular outcome that
appropriately deals with the stress.  Important to the ability of p53 to suppress
tumorigenesis is transcriptional regulation of target genes.  The p53 pathway is
activated by many different types of cellular stress including (but not limited to)
DNA damage, oncogene activation, hypoxia, heat shock, and glucose starvation
(Pluquet and Hainaut, 2001; Levine et al., 2006).  As described earlier, in the
absence of stress, p53 levels are maintained at low steady-state levels through
the interaction with MDM2, the E3-ubiquitin ligase of p53 (Honda et al., 1997).
MDM2 ubiquitinates the C-terminus of p53, resulting in rapid turnover of the
protein by way of degradation by the 26S proteasome.  In the event of cellular
stress, p53 is post-translationally modified and activated as described in the
previous section, resulting in increased levels of p53 protein.  Activated p53
binds in a sequence-specific manner to regions of DNA containing p53
consensus binding sites (Kern et al., 1991; El-Deiry et al., 1992).  In the majority
of p53-regulated genes identified to date, a p53 consensus binding site is present
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in the promoter region or the first or second intron of the gene (El-Deiry et al.,
1992).
p53 transcriptionally activates downstream target genes corresponding to
the type and extent of the cellular stress that activated p53.  The protein products
of the target genes activated by p53 span a wide range of functions, and result in
several distinct cellular outcomes.  The most well-known and understood
pathways related to p53-mediated tumor suppression include cell cycle arrest,
apoptosis, and DNA repair (Levine et al., 2006).  p53 target genes have been
identified and play distinct roles in these processes.  Key target genes involved in
cell cycle arrest, apoptosis, and DNA repair will be described in more detail.
Cell Cycle Arrest
Key players in p53-mediated cell cycle arrest include p21 and 14-3-3σ.
p21, also known as cyclin-dependent kinase (Cdk)-interacting protein (Cip1) or
wild-type p53-activated fragment 1 (WAF1), was first identified using two different
strategies.  Harper et al. (1993) used a yeast two-hybrid screen to identify Cdk-
interacting proteins (Cips), whereas El-Deiry et al. (1993) used subtractive
hybridization to detect genes induced by wild-type p53, but not mutant.  In these
early studies, p21 was shown to interact with Cdk2 and inhibit its kinase activity.
In addition, it inhibited the phosphorylation of retinoblastoma protein (Rb) by
cyclin-Cdk complexes involved in the G1-S transition of the cell cycle (Harper et
al., 1993).  Simultaneously, p21 was induced by p53 in multiple cell lines and is
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conserved across species.  Upon expression of p21 in cancer cells, cell growth
was inhibited (El-Deiry et al., 1993).  The combined data from these studies
implicated p21 in p53-mediated G1-arrest.
Another p53 target gene that plays a role in cell cycle arrest is 14-3-3σ.
14-3-3σ was isolated using serial analysis of gene expression (SAGE) to
compare genes upregulated in colorectal cancer cells in response to ionizing
radiation (IR), in a p53-dependent manner.  When overexpressed, 14-3-3σ
causes a G2/M arrest in multiple cell lines (Hermeking et al., 1997).  The
mechanism by which 14-3-3σ mediates a G2/M arrest is by sequestering cell
division cycle 2 (Cdc2)-cyclin B1 complexes in the cytoplasm in response to DNA
damage (Chan et al., 1999).  Cdc2-cyclin B1 must translocate to the nucleus to
allow entry into mitosis (Jin et al., 1998).
Apoptosis
p53 target genes have been implicated in both extrinsic and intrinsic
pathways of apoptosis.  The extrinsic apoptotic pathway involves binding of
death ligands to death receptors and a resulting cell death cascade. Fas/APO-1
(also known as CD95) is a member of the tumor necrosis factor receptor (TNFR)
superfamily.  Upon binding of Fas ligand to the Fas receptor, the receptor
homotrimerizes.  The trimerized cytoplasmic domain recruits an adaptor, Fas-
associating factor with death domain (FADD), which in turn recruits caspase-8.
Oligomerization of caspase-8 results in activation by self-cleavage, followed by
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activation of a caspase cascade that modulates apoptosis (Ashkenazi and Dixit,
1998).  In cancer cell lines treated with chemotherapeutic agents, an increase in
apoptosis was observed.  A corresponding increase in the cell-surface
expression of the Fas/APO-1 receptor occurred in the cells, but only in the
presence of wild-type p53.  Further investigation revealed a p53-consensus
binding site in the first intron of the Fas/APO-1 gene to which p53 is able to
activate transcription in luciferase assays (Muller et al., 1998).
Another p53 target gene involved in the extrinsic pathway of apoptosis is
KILLER/DR5 (also called APO-2), a member of the TNF-related apoptosis
inducing ligand (TRAIL) family of death receptors.  Little is known about the
apoptotic signaling cascade that occurs when TRAIL binds to KILLER/DR5
except that it does require caspase activation (Ashkenazi and Dixit, 1998).
KILLER/DR5 was a novel gene identified in a subtractive hybridization screen for
genes upregulated in cancer cells that have chemosensitivity to ADR compared
to cancer cells chemoresistant to ADR.  KILLER/DR5 shows sequence similarity
to previously identified death receptors.  Due to nature of the screen in which it
was identified (induced by ADR), KILLER/DR5 was hypothesized to be a
potential p53 target gene, in that the p53 pathway is strongly induced by ADR.  In
agreement with this hypothesis, KILLER/DR5 was only expressed in response to
DNA damaging agents in the presence of wild-type p53.  In addition, expression
of p53 by adenovirus in cancer cell lines lacking p53 results in upregulation of
KILLER/DR5 (Wu et al., 1997).  Later studies revealed the presence of a p53
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consensus binding site in the first intron of the KILLER/DR5 gene and
subsequent analysis of this site validated KILLER/DR5 as a direct target of p53
(Takimoto and El-Deiry, 2000).
p53 also regulates genes involved in the intrinsic pathway of apoptosis,
which involves disruption of the mitochondrial membrane potential.  Bax is an
example of a p53 target gene that is involved in intrinsic apoptosis.  Bax is a pro-
apoptotic member of the Bcl-2 family.  Bax forms heterodimers with Bcl-2 and
Bcl-XL, both anti-apoptotic proteins, and these interactions serve to maintain a
balance favoring the anti-apoptotic factors (Adams and Cory, 1998).  The Bax
gene contains a p53 consensus binding site in its promoter, through which p53
can upregulate its expression.  Upon upregulation of Bax by p53, the ratio of Bcl-
2 and Bcl-XL to Bax is lowered, and eventually Bax levels reach a point when
they can promote the release of cytochrome c from the mitochondria and initiate
signaling cascades leading to apoptosis (Miyashita and Reed, 1995).
p53-upregulated modulator of apoptosis (PUMA) and Noxa are also pro-
apoptotic Bcl-2 family members that participate in the intrinsic pathway of
apoptosis.  PUMA was identified by two distinct methodologies.  Yu et al. (2001)
performed SAGE on DLD-1 colorectal cancer cells inducibly-expressing p53 to
identify genes upregulated by p53 that mediate apoptosis of these cells upon p53
expression.  Nakano and Vousden (2001) originally identified PUMA in a
microarray comparing changes in gene expression in cells with or without p53.
They performed 5’-rapid amplification of cDNA ends (RACE) to isolate the PUMA
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full-length cDNA.  Though the results of both groups are not completely
concordant, the PUMA gene can be alternately spliced to produce several
proteins.  In addition, a p53 consensus binding site to which p53 can bind and
upregulate expression was identified in the PUMA gene (Yu et al., 2001; Nakano
and Vousden, 2001).  Noxa was identified as a transcript upregulated in mouse
cells treated with x-ray irradiation in a p53-dependent manner (Oda et al., 2000).
Regulation of Noxa is achieved by p53 binding a p53 consensus binding site in
the Noxa promoter and activating its transcription.  PUMA and Noxa are BH3-
only members of the Bcl-2 family that are able to bind and inhibit anti-apoptotic
Bcl-2 members in the mitochondria.  This inhibition results in the release of
cytochrome c and activation of apoptosis (Yu et al., 2001; Nakano and Vousden,
2001; Oda et al., 2000).
DNA Repair
Examples of p53 target genes involved in DNA repair are p48 (DDB2) and
p53-inducible ribonucleotide reductase small subunit 2 homologue (p53R2).  p48
plays a role in nucleotide excision repair (NER) and aids in the removal of lesions
in DNA caused by UV.  People affected with xeroderma pigmentosum (XP) have
defects in nucleotide excision repair.  XP complementation group E (XPE)
consists of people with a mutation in the p48 gene.  p48 is one of two subunits in
a UV-damaged DNA binding protein (UV-DDB).  Previous observations indicated
that p48 was upregulated in response to UV in cells containing wild-type p53, but
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not in cells deficient for p53.  A p53 consensus binding site was identified in the
5’ untranslated region (UTR) of the p48 gene.  p53 is able to bind to this site in
vitro and activate transcription from this site in luciferase assays (Tan and Chu,
2002).
p53R2 was identified using differential display to compare genes
upregulated upon inducible expression of p53 in SW490 cells to genes
upregulated upon inducible expression of mutant p53.  The p53R2 protein has
80% identity to the small subunit (R2) of ribonucleoside reductase (Tanaka et al.,
2000).  Ribonucleotide reductase converts ribonucleotide diphosphates to
deoxyribonucleotides (dNTPs) to be used in synthesis of DNA.  A p53 consensus
binding site is located in the first intron of the p53R2 gene.  p53 exhibits in vitro
binding to this site and activates transcription in luciferase assays.  Increased
expression of p53R2 is observed in MCF7 breast cancer cells after DNA damage
(Tanaka et al., 2000).  p53R2 is a p53-inducible subunit induced in response to
DNA damage.  Upregulation of p53R2 enables a dNTP supply to be available for
DNA repair in response to damage.
The p53-MDM2 interaction was discussed earlier as the mechanism by
which levels of p53 are kept at low steady-state levels in the absence of stress.
When stress occurs, p53 and MDM2 dissociate and allow for the transcriptional
activation of target genes by p53.  One p53 target gene that is induced in
response to stress is the MDM2 gene.  The MDM2 gene contains two adjacent
binding sites in intron 1 (Zauberman et al., 1995).  The upregulation of MDM2 by
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p53 in response to damage demonstrates another way in which feedback
regulation is maintaining the balance between p53 and MDM2.  The multiple
levels of feedback control illustrate the importance of the MDM2/p53 interaction,
and therefore its stringent regulation.  The p53 targets described above exemplify
the diverse pathways by which p53 is able to mediate tumor suppression.
p53 Family Members
p63 and p73 were identified to be homologues of p53 (Yang et al., 1998;
Kaghad et al., 1997).  Using knockout studies in mice, p63 and p73 were found
to play very different roles than p53 during development and in adult tissue.  p63
is essential for the proper development of skin and epithelial structures during
embryogenesis (Mills et al., 1999; Yang et al., 1999).  In contrast, p73 is involved
in the development of neural structures, such as the hippocampus, as well as
proper pheromonal signaling, and regulating fluid dynamics of the cerebrospinal
fluid (Yang et al., 2000).
Both the p63 and p73 genes contain two transcriptional start sites and
make use of alternative splicing to produce at least six p63 or p73 proteins (Yang
and McKeon, 2000).  Importantly, all p63 and p73 proteins contain a DNA binding
domain having 60% sequence identity to the DNA binding domain of p53 (Yang
and McKeon, 2000).  At least three of each of the p63 and p73 proteins also
contain a transactivation domain with 25% sequence homology to that of p53,
and are referred to as TAp63 and TAp73 (Yang and McKeon, 2000).  Other p63
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and p73 proteins lack the transactivation domain and are designated ΔNp63 and
ΔNp73 (Yang and McKeon, 2000).  It is thought that ΔNp63 and ΔNp73 can act in
a dominant negative fashion to inhibit the function of not only the TAp63 and
TAp73 proteins, but also p53 (Yang and McKeon, 2000).  In the case of ΔNp63α,
which is the most abundantly expressed p63 protein in many different squamous
epithelial cells and glandular tissues (Westfall and Pietenpol, 2004), the protein
exhibits transcriptional repressor activity and represses transcription at various
p53 target gene promoters in vitro (Westfall et al., 2003).  A role for p63 and p73
in p53-dependent apoptosis was proposed from results generated using E1A-
expressing mouse embryonic fibroblasts (MEFs) derived from animals lacking
the expression of p53, p63, p73, or combinations of the family members (Flores
et al., 2002).  E1A MEFs lacking p53 and p63 or p53 and p73 are more resistant
to apoptosis induced by treatment with DNA damaging agents than E1A MEFs
lacking p53 alone, suggesting that p63 and p73 are necessary for p53 to elicit a
full apoptotic response in this model system (Flores et al., 2002).  However, in a
model system utilizing T lymphocytes lacking p53, p63, p73, or p63 and p73, p63
and p73 are not required for p53-mediated apoptosis in response to ionizing
radiation (Senoo et al., 2004).  Clearly, further investigation is required to
understand the roles of p63 and p73 in p53-mediated signaling and was a goal of
the current study.
A major source of debate exists over whether, like p53, p63 and p73 act
as tumor suppressors, and their precise roles in the development of cancer in
24
humans.  Very few human cancers exhibit mutations in p63 or p73 (Yang et al.,
2002).  Examination of mice heterozygous null for p53, p63, and p73 or
combinations of the three family members revealed the spontaneous generation
of tumors in mice of all genotypes.  The p53, p63, and p73 heterozygous null
mice displayed tumor spectra unique for each genotype.  Mice heterozygous null
for both p53 and p63 or p53 and p73 exhibited higher tumor burden and tumors
with greater metastatic potential than mice heterozygous null for p53, p63, or p73
alone (Flores et al., 2005).  Though these recent data suggest a role for p63 and
p73 as tumor suppressors, the opposite results were observed for p63.  Mice
heterozygous null for p63 did not form spontaneous tumors (Keyes et al., 2006).
The conflicting results could be due to differences in the mouse models used for
the studies.  Additional investigation will be required to determine what role these
family members play in human tumorigenesis.
Selectivity of p53 Response
p53 regulates the transcription of many genes that play roles in p53-
mediated cell cycle arrest, DNA repair, and apoptosis (El-Deiry, 1998; Levine et
al., 2006).  In response to cell stress, p53 binds to DNA in a sequence-specific
manner (Kern et al., 1991) to a consensus site in a regulatory region of the gene
(promoter or intron) (El-Deiry et al., 1992).  The stresses that activate p53
signaling are many (Levine et al., 2006) and how p53 mediates a response
should be tailored to the type and extent of damage, as well as the overall
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outcome that is appropriate under the circumstances.  However, the mechanism
by which p53 selectively regulates its many target genes is still not well defined.
Many factors are believed to contribute to the ability of p53 to
discriminately regulate target genes.  One such factor is the differential affinity of
p53 for consensus DNA binding sites.  In vitro, p53 has higher affinity for
consensus binding sites of genes involved in cell cycle arrest and DNA repair
than the binding sites of genes implicated in apoptosis (Szak et al., 2001; Kaeser
and Iggo, 2002; Weinberg et al., 2005).  Reporter-based transcriptional assays in
yeast and mammalian cells revealed that p53 has higher transcriptional activity
when activity was assayed on consensus binding sites from cell cycle arrest,
DNA repair, and death receptor apoptotic target genes versus sites from genes
involved in mitochondrial apoptosis (Qian et al., 2002).  The “match” of a target
gene consensus binding site to the ideal consensus binding site may also affect
the affinity of p53 to that site.  Using chromatin immunoprecipitation, Kaeser and
Iggo (2004) observed a two-fold higher occupancy of p21 site 1 (distal site),
which has an 18/20 bp match to the consensus, than p21 site 2 (proximal site),
which has a 12/20 bp match, by p53 transfected into H1299 cells.
Post-translational modifications of p53 are also thought to play a role in
the ability of p53 to selectively regulate target genes.  Phosphorylation and
acetylation of p53 enhance p53 protein stability in part through disruption of the
p53-MDM2 interaction (Bode and Dong, 2004; Appella and Anderson, 2001).  Of
note, post-translational modifications of MDM2 also contribute to the disruption of
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the p53-MDM2 interaction (Brooks and Gu, 2003).  Post-translational
modifications of p53 also increase the ability of p53 to bind to DNA and facilitate
interactions with other chromatin-associated proteins (Bode and Dong, 2004;
Appella and Anderson, 2001).  For example, phosphorylation of p53 on S15
results in enhanced binding of p53 to CBP/p300, a histone acetyltransferase
(Lambert et al., 1998).  CBP/p300 acetylates p53 at multiple C-terminal lysine
residues in vitro and in cells, which then serves to enhance the ability of p53 to
bind DNA (Gu and Roeder, 1997; Luo et al., 2004).  In addition, p53
phosphorylated on S46 was shown to have a higher affinity for apoptotic target
gene promoters compared to non-apoptotic gene promoters (Mayo, et al., 2005).
The many forms of stress that challenge a cell lead to differential post-
translational modifications of p53 (Bode and Dong, 2004; Appella and Anderson,
2001), resulting in distinctly modified forms of the p53 protein.  Depending on the
post-translational modifications, p53 exhibits distinct properties of stability, DNA
binding ability or affinity, interactions with other proteins, and chromatin access.
All of these factors likely contribute to the ability of p53 to differentiate between
target genes.
Another aspect that may dictate differential p53-mediated transcription of
target genes is the timing of p53 binding to regulatory regions and subsequent
recruitment of the basal transcriptional machinery.  Espinosa et al. (2003)
showed that p53 is constitutively bound to both consensus binding sites in the
p21 promoter.  In addition, members of the basal transcriptional machinery,
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including RNA polymerase II, are constitutively bound to the proximal promoters
of p53 target genes involved in cell cycle arrest and DNA repair, but not
apoptosis (Espinosa et al., 2003).  However, it remains unclear whether there is
a direct relationship between the constitutive binding of p53 to a target gene
consensus binding sites and the presence of basal transcriptional machinery
bound to the proximal promoter of those target genes.  Further studies are
necessary to clarify the role of p53-mediated recruitment of basal transcriptional
machinery in the timing of regulation and selection of target genes.
Finally, occupancy of consensus binding sites of target genes by other
p53 family members, p63 and p73, could also play an important role, whether
cooperative or antagonistic, in p53-mediated signaling.  Again, all p63 and p73
proteins contain a DNA binding domain having 60% sequence identity to the
DNA binding domain of p53.  In addition, ΔNp63 and ΔNp73 can act in a
dominant negative fashion to inhibit the function of not only the TAp63 and
TAp73 proteins, but also p53 (Yang and McKeon, 2000), so this may impact p53-
selectivity of target genes.  My dissertation research aimed to further understand
p53 target gene selectivity.
Dissertation Research Goals
The ability of p53 to upregulate target genes in response to genotoxic
stress is crucial for suppression of tumorigenesis.  The goal of my dissertation
research was to elucidate mechanistic details of p53 select target gene
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regulation in response to stress with emphasis on the roles of the p53 family
members in these processes.  To achieve this goal, I determined common and
distinct target genes of p53 and p63, including both known and previously
unidentified targets.  I also examined the binding of transcription factors to
regulatory regions in p53 target genes.  Using a primary human epidermal
keratinocyte (HEK) model system for these studies was important so as to avoid
genetic and epigenetic changes that occur in cell lines over time.
My first aim was to identify novel p53 candidate target genes from HEKs
treated with a DNA-damaging agent, ADR.  To achieve this goal, I used a
chromatin immunoprecipitation/yeast screen method developed in our lab.  An
advantage of this method is that we are only screening fragments of DNA that
are directly bound by p53.  This ensures that any putative candidate genes are
direct targets.  Concordantly, I performed microarray analyses to determine the
gene expression profile of HEKs infected with an adenovirus expressing p53.
Not only did this provide more information about target gene expression in HEKs,
it also helped prioritize candidate target genes for validation.  Finally, in a parallel
microarray experiment, I examined the gene expression profile of HEKs infected
with an adenovirus expressing ΔNp63α to identify distinct and overlapping
patterns of gene expression compared to p53.  The analysis of my library screen
and microarrays can be found in Chapter III.
My second aim was to identify factors involved in the selective regulation
of target genes by p53, particularly focusing on the involvement of transcription
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machinery (RNA polymerase II), p53 family members (ΔNp63α), and p53 post-
translational modifications (S15 phosphorylation).  Previous studies suggest that
one property of p53 target gene selectivity results from the differential types and
timing of transcription factor binding (Espinosa et al., 2003).  My studies hoped to
expand these findings by examining a diverse number of p53 target genes in a
primary cell culture system.  In the determination in the differences in
transcription factor binding, I was interested in both constitutive binding and the
binding changes that occurred at target gene regulatory regions in response to
stress.  Chromatin immunoprecipitation (ChIP) was employed for these
experiments and the data are presented in Chapter IV.
Overall, these studies resulted in identification of novel target genes of
p53 and ΔNp63α.  In addition, a subset of target genes was found to be inversely
regulated by p53 and ΔNp63α.  Examination of binding of p53 and ΔNp63α to
target gene consensus binding sites also revealed an inverse pattern of binding.
Finally, my studies indicate that the location of a p53 consensus binding site may
dictate the constitutive binding of basal transcription machinery.  These
conclusions and their implications will be discussed in Chapter V.
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CHAPTER II
EXPERIMENTAL PROCEDURES
Cell Culture and Treatment
Primary human epidermal keratinocytes (HEKs) were obtained from the
Vanderbilt Skin Disease Research Core.  Cells (passages 3 through 5) were
cultured in EpiLife M-EPI-500 keratinocyte growth media (Cascade Biologics,
Portland, OR) supplemented with human keratinocyte growth supplement #S-
001-5 (Cascade Biologics), 0.06 mM CaCl2 #S-013-EPI (Cascade Biologics), and
1% penicillin-streptomycin (v/v).  The human colorectal carcinoma HCT116 p53
+/+ and p53 -/- cell lines were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum (v/v) and 1% penicillin-
streptomycin (v/v).  All cells were incubated in a humidified incubator at 37°C
under 5% CO2.  ADR was obtained from the Vanderbilt Chemotherapy
Pharmacy.  For the experiments in Chapter III, ADR was used at a final
concentration of 0.35 µM.  For the experiments in Chapter IV, ADR was used at a
final concentration of 0.5 µM.  Cells were harvested after treatment for the
indicated times.  For treatment with UV, cells were rinsed once with phosphate
buffered saline (PBS), which was aspirated immediately prior to exposure to 50
J/m2 UV-C (UV) using a UV Stratalinker 1800 (Stratagene, La Jolla, CA).  After
UV treatment, conditioned media was replaced, and cells were harvested at the
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indicated timepoints.  For the microarray experiments, cells were infected with
adenoviruses expressing GFP, p53, or ΔNp63α for 30 h.
Immunoblot Analysis
Whole cell lysates were prepared by washing cells with ice-cold PBS,
scraping cells in ice-cold radioimmunoprecipitation assay (RIPA) buffer (150 mM
NaCl, 1% Nonidet P-40 [v/v], 0.5% deoxycholic acid [w/v], 0.1% SDS [w/v], 50
mM Tris [pH 8.0], 5 mM EDTA), and frozen immediately at -80˚C.  Lysates were
supplemented with 50 mM sodium fluoride, 0.2 mM sodium vanadate, and the
protease inhibitors chymostatin (10 µg/ml) (Sigma), leupeptin (10 µg/ml) (Sigma),
antipain (10 µg/ml) (Sigma), pepstatin A (10 µg/ml) (Sigma), and 4-(2-
aminoethyl)-benzenesulfonylfluoride (200 µg/ml) (Calbiochem, San Diego, CA)
while thawing on ice.  Lysates were clarified at 13,000 x g for 15 min at 4˚C.
Protein concentration was determined using the Bio-Rad DC Protein Assay Kit
(Bio-Rad Laboratories, Hercules, CA).  Fifty µg of whole cell lysate were boiled in
1X Laemmli sample buffer.  Proteins were resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) on a 10% polyacrylamide gel,
transferred to an Immobilon-P membrane (Millipore, Bedford, MA), and blocked
with 5% nonfat dry milk (w/v) in TTBS (100 mM Tris-HCl pH [7.5], 150 mM NaCl,
0.1% Tween-20 [v/v]) for at least 1 h.  Primary antibodies included RNA
polymerase II N-20 (Santa Cruz Biotechnology, Santa Cruz, CA), p53 DO-1
(Santa Cruz), p63 4A4 (Santa Cruz), phospho-Ser15-p53 (P-S15-p53) catalogue
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#9284 (Cell Signaling, Beverly, MA), MDM2 SMP14 (Santa Cruz), p21WAF1 Ab-1
(Oncogene Research Products, Boston, MA), and β-actin I-19 (Santa Cruz).
Secondary antibodies were isotype-specific horseradish peroxidase conjugates
(Sigma).  Bands were visualized with enhanced chemiluminescence using the
ECL Western Blotting Detection Reagents (Amersham Biosciences, Piscataway,
NJ).
Formaldehyde Crosslinking and Chromatin Immunoprecipitation
Prior to crosslinking, growth medium was aspirated and cells were rinsed
once with PBS.  Cells were crosslinked with a 1.6% formaldehyde solution (v/v)
(EMD Chemicals, Inc., Gibbstown, NJ) in PBS for 13 min at room temperature.
Crosslinking was stopped by the addition of glycine to a final concentration of
0.125 M and allowed to incubate at room temperature for 2 min.  Non-crosslinked
cells were treated with identical volumes of PBS.  Crosslinked and non-
crosslinked monolayers were rinsed twice with PBS.  Lysates were harvested by
scraping cells in 1 ml of RIPA buffer and frozen immediately at -80˚C.
Phosphatase and protease inhibitors were added to lysates on ice as described
above.  Lysates were sonicated to yield chromatin fragments of approximately 1
kb and clarified by centrifugation at 13,000 x g for 15 min at 4˚C.  Protein
concentration was determined using the Bio-Rad DC Protein Assay Kit.  Lysates
were divided into aliquots and 2 mg of each protein extract were precleared with
10 µ g of mouse IgG bound to protein A sepharose (PAS) beads (p53
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immunoprecipitation) or 20 µg rabbit IgG bound to PAS beads (p63, pol II, P-
S15-p53 immunoprecipitations) for at least 1 h at 4˚C.  After centrifugation for 30
s at 13,000 x g at 4˚C, supernatants were transferred to new tubes containing a
30-µl bed volume of PAS beads, and 2 µg of the appropriate antibody was
added.  Antibodies used in the chromatin immunoprecipitations included 1 µg of
both Pab 1801 (Santa Cruz) and Ab-1 (Oncogene Research Products) for p53,
H-129 (Santa Cruz) for p63, N-20 for RNA polymerase II, and phospho-Ser15-
p53 #9284 for P-S15-p53.  Formaldehyde-crosslinked lysates were also
immunoprecipitated with cyclin B1 GNS1 (Santa Cruz) and Bax N-20 (Santa
Cruz) as isotype-specific control antibodies for the p53 and p63/pol II/P-S15-p53
immunoprecipitations, respectively.  Immunoprecipitations were performed by
rocking overnight at 4˚C.
Immunocomplexes were washed twice with ice-cold RIPA buffer, four
times with ice-cold IP wash buffer (100 mM Tris pH [8.5], 500 mM LiCl, 1%
Nonidet P-40 [v/v], 1% deoxycholic acid [w/v]), and twice more with ice-cold RIPA
buffer.  PAS beads were aspirated dry with a 30-gauge needle and 200 µl of
Crosslinking Reversal Buffer (125 mM Tris pH [6.8], 10% β-mercaptoethanol
[v/v], 4% SDS [w/v]) was added.  Samples were heated at 100˚C for 30 min, and
then the DNA was isolated from the immunoprecipitated chromatin by phenol-
chloroform extraction and ethanol precipitation.  DNA was resuspended in 40 µl
nuclease-free water (30 µ l for the pol II IP) and 2 µ l were added to each
polymerase chain reaction.
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Genomic input DNA was isolated from cells that were formaldehyde-
crosslinked, harvested, and sonicated identically to the other experimental plates.
After sonication and protein concentration determination, 1 mg of protein extract
was incubated in a boiling water bath for 30 min.  The boiled lysate was phenol-
chloroform extracted and ethanol precipitated to isolate the DNA.
ChIP PCR Amplification
The primer sequences used in the polymerase chain reactions (PCR) are
listed in Table 1.  PCR conditions for all primer sets listed were optimized using
genomic input DNA. The p21 consensus binding site 1, 14-3-3σ consensus
binding site 2, p53R2 consensus binding site, Fas/APO1 consensus binding site,
MDM2 consensus binding site, p21 proximal promoter, 14-3-3σ proximal
promoter, RRAD putative consensus binding site, and MOAP1 putative
consensus binding site polymerase chain reactions were performed in a final
concentration of 50 mM KCl, 10 mM Tris pH [9.0], 0.1% Triton X-100 [v/v], 0.75
mM MgCl2, 0.25 mM dNTPs, 0.2 µM each primer, and 1.25 U Taq (Promega,
Madison, WI).  The p48 consensus binding site/proximal promoter, Noxa
consensus binding site, p53R2 proximal promoter, Noxa proximal promoter,
Fas/APO1 proximal promoter, and MDM2 proximal promoter polymerase chain
reactions were performed in a final concentration of 16.6 mM (NH4)2SO4, 0.67
mM Tris pH [8.8], 6.7 mM MgCl2, 10 mM β-mercaptoethanol, 10% dimethyl
sulfoxide [v/v], 1.5 mM dNTPs, 7 ng/µl each primer, and 1.25 U Taq.  The p21
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consensus binding site 2 and 14-3-3σ consensus binding site 1 polymerase
chain reactions were performed using Ready-to-Go PCR beads (Amersham
Biosciences) according to manufacturer’s instructions with a final primer
concentration of 0.4 µM.  PCR conditions for p21 consensus binding site 1, p21
consensus binding site 2, 14-3-3σ consensus binding site 2, p53R2 consensus
binding site, and Fas/APO1 proximal promoter were 1 cycle of 95˚C, 5 min, 40
cycles of 95˚C, 30 s/ (annealing temperature listed in Table 1), 45 s/ 72˚C, 30 s,
followed by 1 cycle of 72˚C, 10 min.  PCR conditions for 14-3-3σ consensus
binding site 1, p48 consensus binding site/proximal promoter, Noxa consensus
binding site, Fas/APO1 consensus binding site, MDM2 consensus binding site,
p21 proximal promoter, 14-3-3σ proximal promoter, p53R2 proximal promoter,
Noxa proximal promoter, and MDM2 proximal promoter were 1 cycle of 95˚C, 5
min, followed by 40 cycles of 95˚C, 1 min/ (annealing temperature listed in Table
1), 1 min/ 72˚C, 1 min, followed by 1 cycle of 72˚C, 5 min.  PCR conditions for
RRAD putative consensus binding site and MOAP1 putative consensus binding
site were 30 or 35 cycles (respectively) of 94˚C, 45 s/(annealing temperature
listed in Table 1), 1 min/72˚C 25 s, followed by 1 cycle of 72˚C, 5 min.  To ensure
linearity of each polymerase chain reaction, increasing amounts of genomic input
were added to separate polymerase chain reactions to be sure corresponding
increasing amounts of signal were visualized on 6% polyacrylamide gels
(acrylamide-bisacrylamide [19:1]) in 1X Tris acetate-EDTA buffer.  Gels were
stained with ethidium bromide and destained with water.
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Real-time PCR Amplification
For the gene expression analysis in Figures 1, 3 through 8, and 10 total
RNA was isolated from cells using the Aurum Total RNA Mini Kit (Bio-Rad
Laboratories, Hercules, CA).  Reverse transcription of 500 ng of total RNA was
performed using the Taqman Reverse Transcription Reagents Kit (Applied
Biosystems, Foster City, CA).  For the gene expression analysis in Figure 9, cells
were trypsinized, pelleted by centrifugation, and resuspended in RNA lysis buffer
(10 mM Tris pH [7.5], 100 mM NaCl, 2 mM EDTA, 1% SDS [w/v]).  Lysis was
completed by passage through a 23-gauge needle eight times.  Proteinase K
was added to the lysate to a final concentration of 100 µg/ml and incubated at
37°C for 1 h.  After digestion by proteinase K, the NaCl concentration was
increased to 400 mM.  Samples were heated at 65°C for 5 min with constant
agitation, followed by immediate cooling in ice water for 30 sec.  mRNA was
isolated by incubation with oligo-dT cellulose (Ambion Inc., Austin, TX) with
rocking at room temperature for at least 2 h.  The mRNA-oligo-dT cellulose
mixture was washed twice with high-salt buffer (10 mM Tris pH [7.5], 400 mM
NaCl, 1 mM EDTA, 0.2% SDS [w/v]) and packed with high-salt buffer on a poly
prep chromatography column (Bio-Rad).  The oligo-dT cellulose was washed
once with high-salt buffer and once with low-salt buffer (10 mM Tris pH [7.5], 100
mM NaCl, 1 mM EDTA, 0.2% SDS [w/v]).  The mRNA was eluted from the oligo-
dT cellulose with 55°C elution buffer (5 mM Tris [pH 7.5], 1 mM EDTA, 0.2% SDS
[w/v]).  mRNA was ethanol precipitated by adding two volumes of 95% ethanol,
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sodium acetate (pH [5.2]) to a final concentration of 220 mM and incubation
overnight at -20°C.  After precipitation, mRNA was pelleted by centrifugation at
12,000 x g for 30 min and the pellet was rinsed once with 70% EtOH.  The
mRNA pellet was dried in a centrifugal evaporator (Speed-Vac® type) for 5 min
and resuspended in diethylpyrocarbonate (DEPC)-treated sterile H2O.  Reverse
transcription of 100 ng of mRNA was performed using the Taqman Reverse
Transcription Reagents Kit (Applied Biosystems). Real-time PCR was performed.
Each reaction contained reverse transcribed RNA in a final concentration of 1X
iQ SYBR-Green Supermix (Bio-Rad) and 0.2 µM of each primer.  Real-time
polymerase chain reactions were run on an iCycler Thermal Cycler (Bio-Rad).
PCR conditions were 1 cycle of 95˚C, 3 min, 40 cycles of 95˚C, 10 s/ (annealing
temp.), 45 s.  The primers used in real-time PCR were designed using Beacon
software (Bio-Rad).  Primer sequences and annealing temperatures are listed in
Table 2.  Gene expression was determined by normalizing each sample to the
housekeeping gene glyceraldehyde dehydrogenase (GAPDH), and fold-change
was calculated relative to controls.
Microarray Analysis
HEKs were infected with adenoviruses expressing GFP, p53, or ΔNp63α
for 30 h.  Cells were harvested by trypsinization and pelleted by centrifugation at
1000 rpm for 5 min.  mRNA was isolated as described above and submitted to
the Vanderbilt Microarray Shared Resource (VMSR).  Two independent replicate
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experiments were analyzed.  Using Agilent’s Bioanalyzer microfluidic assay
(Agilent Technologies, Palo Alto CA), the VMSR determined the amount of
mRNA degradation, as well as protein and DNA contamination.  After confirming
the mRNA was of high enough quality to use in the analysis, the mRNA was
processed using the standard Affymetrix protocol (Affymetrix Inc, Santa Clara,
CA).  Briefly, mRNA (300 ng) was reverse transcribed to double-stranded (ds)
cDNA using an oligo-dT primer coupled to a T7 promoter.  T7 polymerase was
used to transcribe from the ds cDNA in vitro and incorporate biotin-modified CTP
and UTP ribonucleotides.  The biotinylated cRNA (15 µg) was fragmented and
hybridized to the Affymetrix GeneChip U133 Plus 2.0.  Following hybridization for
16 h at 45°C, hybridized cRNAs were washed and detected through streptavidin
coupled to phycoerythrin using the Affymetrix 450 Fluidics Station and
recommended protocols.  Results were visualized by laser scanner (Affymetrix
GeneChip Scanner 3000) and the image data quantified to generate gene
expression values and ratios of gene expression between the hybridized
samples.  Microarray data analyses were performed using the GeneSpring
software platform (Silicon Genetics, Redwood City, CA).  Data were normalized
on a per chip basis to the 50th percentile, then normalized on a per gene basis to
the median signal, and finally normalized with the robust multichip average
(RMA) normalization algorithm on a per gene basis to generate ratios of p53- or
ΔNp63α-infected cells compared to GFP-infected cells for each replicate.
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Generation and Screening of HEK ChIP Library
HEKs were treated with ADR for 6 h.  Crosslinking, sonication, and protein
concentration determination was performed as described above.  Thirty-two mg
of lysate were precleared and immunoprecipitation with anti-p53 antibodies was
performed as described above.  Immunoprecipitations were washed as
described, followed by protein degradation in digestion buffer (120 µg/ml
Proteinase K, 10 mM Tris pH [7.5], 5 mM EDTA, and 0.5% SDS [w/v]) at 56°C
overnight, and then 65°C for 30 min.  DNA was isolated by phenol-chloroform
extraction and ethanol precipitation.  The p53-immunoprecipitated DNA was
processed using a PCR Polishing Kit (Pfu-based; Stratagene, La Jolla, CA)
according to the manufacturer’s instructions.  pBM947 (a HIS3 reporter plasmid
generously provided by M. Johnston at Washington University in St. Louis, MO)
was blunted at the BamHI restriction enzyme sites.  A blunt ligation was
performed to insert the polished DNA fragments into the blunted vector and the
ligated vector was amplified by growth in TransforMax EPI300 Electrocompetent
Escherichia coli (Epicentre, Madison, WI).  A total of 100 µg of pBM947-based
library DNA were transformed into Saccharomyces cerevisiae yeast strain
YPH681 containing the pRS314SN vector.  Transformation competent yeast cells
(50 µl aliquots) were centrifuged at 6000 rpm for 15 s and the supernatant was
removed.  To the cell pellet (in the following order): 33% polyethylene glycol
(PEG; 50% [w/v]) (Sigma), 100 mM LiAc (Sigma), 278 µg/ml boiled salmon-
sperm DNA (Sigma), 5.0% DMSO (v/v) (Sigma), and 1 µg library DNA were
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added, brought to a final volume of 360 µl with sterile H2O.  The transformation
reactions were mixed vigorously using a vortex and incubated at 30°C for 30 min,
followed by a 42°C incubation for 30 min. The yeast were pelleted by
centrifugation at 6000 rpm for 15 s, washed once, and resuspended in sterile
H2O.  The transformed yeast were plated onto selection media containing
galactose/lacking tryptophan, uracil, and histidine, followed by incubation at 30°C
for 6 days.  Colonies were replica plated onto synthetic drop out media
containing dextrose/lacking tryptophan, uracil, and histidine for 6 days to screen
for false positives.  Yeast colony PCR was used to amplify the pBM947-based
library DNA fragments from the yeast that grew in a p53-dependent manner.  An
approximate 0.25-µl scrape of yeast cells were added to each polymerase chain
reaction containing 10 mM Tris pH [9.0], 50 mM KCl, 0.1% Triton X-100 [v/v], 0.5
mM MgCl2, 0.25 mM nucleotides, 20 pmol of each primer, and 1.25 U Taq.  PCR
conditions were 1 cycle of 95˚C, 4 min, 50 cycles of 95˚C, 1 min/ 56˚C, 1 min/
72˚C, 1.5 min, followed by 1 cycle of 72˚C for 10 min.  PCR products were
resolved in a 1% [w/v] agarose gel, stained with ethidium bromide, gel purified,
and sequenced.
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CHAPTER III
IDENTIFICATION OF P53 TARGET GENES USING A CHROMATIN
IMMUNOPRECIPITATION/YEAST SCREEN AND MICROARRAY ANALYSES
Introduction
p53 is a tumor suppressor protein known to be mutated in approximately
half of all human cancers and exhibits its tumor suppressive functions through its
ability to mediate cell cycle arrest, DNA repair, and apoptosis in response to
genotoxic stress (Stewart and Pietenpol, 2001).  A major biochemical activity of
p53 is its ability to bind DNA and regulate transcription (Kern et al., 1991; Kern et
al., 1992).  p53 is a sequence specific transcription factor (El-Deiry et al., 1992)
that controls the transcription of many genes, the majority of which are
transcriptionally activated, though repressed genes have also been identified (El-
Deiry, 1998; Tokino and Nakamura, 2000).  p53 activates different subsets of
target genes in response to a variety of cellular stresses, often in a cell type
specific manner (Yu et al., 1999).  To better understand p53 signaling pathways,
considerable research has been done to identify target genes of p53.  Through
these efforts, over 100 genes directly regulated by p53 have been identified and
many play key roles in p53-mediated tumor suppression and regulation of
biological pathways (El-Deiry, 1998; Harms et al., 2004; Nakamura, 2004).
However, as seen from the results of knock-out mouse studies, the target genes
identified to date still do not account for all aspects of p53 signaling pathways.  In
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other words, the mechanistic details of p53-mediated cell cycle arrest or
apoptosis, among other pathways, are not completely explained using only the
current target gene information.  In an unbiased screen of all the non-redundant
sequences in chromosomes 21 and 22, it is estimated that there are ~1600 p53
consensus binding sites in the human genome.  Of note, only 22% of these
fragments are located at the 5’ end of a gene, and 36% are found 3’ of a gene
and significantly correlated with noncoding RNAs (Cawley et al., 2004).  The vast
majority of the estimated sites will likely not be functional, but the screen is still
suggestive of many unidentified targets.  In addition, the role of p63, namely the
ΔNp63α protein, in p53-mediated signaling and regulation of targets is still
unclear.
The goal of the research presented in this chapter was to further our
understanding of p53-regulated signaling pathways.  To achieve this goal, we
first identified novel candidate target genes using a chromatin
immunoprecipitation-based screen developed in our laboratory (Hearnes et al.,
2005).  This type of screening would identify candidate p53-regulated target
genes in primary human epidermal keratinocytes (HEKs) on the basis that p53
could bind to and transactivate a consensus binding site in the vicinity of the
candidate.  Furthermore, we used microarray analyses on HEKs expressing
adenoviral-p53 to provide us with additional data to aid in the selection of likely
candidate target genes.  We performed side-by-side microarray analyses of
HEKs expressing adenoviral-ΔNp63α  to compare transcriptional profiles
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regulated by the two of three p53 family members that are expressed in HEKs.
Using these methods, we identified many candidate p53- and ΔNp63α-regulated
target genes containing p53 consensus binding sites that align with the canonical
p53 consensus sequence.  Of particular interest were Ras-related associated
with diabetes (RRAD), modulator of apoptosis 1 (MOAP-1), and zinc finger
protein 90 (ZFP90).  In addition to novel targets, we also identified known target
genes of p53 thus proving the validity of our screening methods.  Interestingly,
we found an overlapping subset of both candidate and known target genes that
are inversely regulated by p53 and ΔNp63α.  Determining the mechanisms of
coordinate regulation of target genes by p53 and ΔNp63α will allow for a better
understanding of the roles of p53 family members in p53-mediated tumor
suppression.
Results
HEK Library Generation/Yeast Screen Analysis
Primary HEKs were used for library generation to minimize the genetic
and epigenetic changes that occur when a cell line is subjected to many rounds
of passaging.  HEKs were treated with ADR (0.35 µM) for 6 h, then
formaldehyde-crosslinked.  Crosslinked lysates were generated, sonicated to
shear the chromatin, and p53-containing immunocomplexes were precipitated
using anti-p53 antibodies.  DNA fragments from the immunoprecipitated
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chromatin were isolated and cloned into the pBM947 yeast vector upstream of
gene essential for histidine biosynthesis.  The library was transformed into the S.
cerevisiae yeast strain YPH681 harboring the pRS314SN vector containing the
p53 gene under the control of a galactose-inducible promoter.  In the presence of
galactose, p53 protein was expressed in the yeast.  If p53 could bind to the
upstream library sequence and activate expression of the histidine biosynthesis
gene, a colony would grow on an agar plate containing growth media deficient in
histidine.  False positives were identified by replica plating the colonies on
histidine-deficient plates containing glucose, in which p53 expression is
repressed.  Any colonies that grew in the presence of glucose had the histidine
gene activated by another factor independent of p53, and were eliminated from
further screening.
Out of the HEK p53 library, approximately 1 x 106 yeast transformants
were screened and 50 grew in a p53-dependent manner.  The library fragment
from each p53-dependent yeast transformant was PCR-amplified and
sequenced.  On the NCBI website, the Human Genome Resources database
was queried using the sequenced clones in the BLAST search function and 34
non-redundant clones were identified.  The cloned fragments were analyzed
using the p53MH algorithm (Hoh et al., 2002) to determine if they contained
putative p53 consensus binding sites.  Of the 34 non-redundant fragments, 97%
contained a p53 consensus binding site.  El-Deiry et al. (1992) defined the p53
consensus site as two repeats of the sequence RRRC(A/T)(T/A)YYY, where R =
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A or G and Y = C or T.  The two 10 bp repeats can be separated by a 0-13 bp
spacer of random sequence.  Of the 34 fragments, 24 (70%) contained binding
sites matching the ideal p53 consensus sequence at 17 out of 20 bp or better.
Of note, 7 of the 34 (20%) total fragments isolated in the library, matched to a
region in the genome that did not contain any known or predicted genes within 20
kb of the fragment.  A representative list of DNA fragments identified in the library
screen is shown in Table 3, as well as where the fragments align to the human
genome, the candidate target genes that are located within 20 kb of the
fragment, and the corresponding putative p53 consensus binding site for each
fragment.
p53 Microarray Analyses
We used microarray technology to provide us with another criterion, ability
to be transcriptionally regulated by p53, for prioritizing the likely candidate target
genes.  HEKs were infected with an adenovirus expressing p53 and mRNA was
isolated 30 h post-infection.  This time point was chosen because 30 h was when
we observed the most robust expression of a majority of known p53 targets.
Comparison of the gene expression profiles from HEKs infected with p53-
expressing adenovirus to control HEKs infected with GFP-expressing adenovirus
identified 866 genes upregulated and 120 genes downregulated at least 2-fold
upon p53 expression.  Among the regulated genes were several known p53
48
49
targets, thereby confirming the activation of p53-signaling pathways by ectopic
expression of adenoviral-p53.
Putative Regulation of RRAD by p53
Of the candidate genes identified with our library screen and microarray
studies, one putative p53 target we further validated and studied was RRAD,
which was first discovered using subtractive library screening to identify genes
involved in insulin-resistance in patients with Type II diabetes (Reynet and Kahn,
1993).  The RRAD protein has GTPase activity (Zhu et al., 1995) and when
overexpressed, is able to negatively regulate insulin-stimulated glucose uptake in
myocyte and adipocyte cell lines (Moyers et al., 1996).  Interestingly, the
GTPase-activating protein (GAP) for RRAD is nm23, a putative tumor metastasis
suppressor.  The RRAD-nm23 interaction is bi-directional in that each protein
could modulate the activity of the other (Zhu et al., 1999).
We identified a DNA fragment in the HEK library screen that aligned 2.4-
kb upstream of the RRAD gene, therefore fitting our criteria for a target
potentially regulated by p53.  Additionally, RRAD transcript levels were
upregulated 2-fold by p53 in our HEK p53 microarray.  Since the RRAD gene
was identified in two independent assays, this increased the likelihood that the
RRAD gene was a bona fide p53 target.  In order to further validate this putative
target gene, we performed chromatin immunoprecipitation in the colorectal
cancer cell line, HCT116, containing wild-type (functional) p53.  Our goal was to
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determine p53 occupancy at the putative consensus binding site in the RRAD
promoter in response to treatment with ADR.  HCT116 cells were treated with
ADR and formaldehyde-crosslinked at 0, 2, and 8 h after treatment.  ChIP
analysis revealed that p53 was bound constitutively to the putative consensus
binding site in the RRAD promoter prior to ADR treatment (Figure 1A).  Increased
p53 binding was observed at the RRAD putative consensus binding site after 2
and 8 h of treatment with ADR.  These results were confirmed in HEKs treated
with ADR, also (Deb Mays, unpublished data).  Using real-time PCR, a
corresponding increase in RRAD mRNA was observed after ADR treatment,
also, but only in HCT116 cells with wild-type p53 (Figure 1B).  Isogenic HCT116
p53 -/- cells did not upregulate RRAD mRNA after treatment with ADR.  The
HCT116 ChIP and real-time PCR data provide further evidence that RRAD is
regulated by p53.  Further validation of the regulation of RRAD by p53 and the
potential role of RRAD in p53-signaling pathways is currently under investigation
in our laboratory.
ΔNp63α Microarray Analyses
Another goal of my dissertation research was to analyze target gene
regulation by the p53 family member p63, namely the ΔNp63α protein, and
compare the gene expression profiles to those obtained from p53-expressing
HEKs.  This goal was achieved using parallel microarray analyses to those
described above.  Cultures of HEKs identical to those infected with GFP- and
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p53-expressing adenovirus were infected with an adenovirus expressing
ΔNp63α.  Microarray analysis was performed to obtain gene expression profiles.
Again, comparison to HEKs infected with GFP-expressing adenovirus
resulted in the identification of 145 genes upregulated and 620 genes
downregulated by ΔNp63α.  Of great interest to us was the identification of a
subset of genes that were inversely regulated by p53 and p63, and are listed in
Table 4.  The majority of these have not been previously identified as targets of
either transcription factor.  Initial validation was performed on two candidate
targets in this list, MOAP-1 and ZFP90.  MOAP-1 was identified as a Bax-
interacting protein in a yeast two-hybrid screen (Tan et al., 2001).  Recent work
has shown that the tumor suppressor Ras association domain family protein 1A
(RASSF1A) interacts with MOAP-1 and utilizes this interaction to activate Bax
(Vos et al., 2006).  To date, functional characteristics of ZFP90 remain to be
elucidated.  The promoter and intronic regions of MOAP-1 and ZFP90 were
analyzed using the p53MH algorithm (Hoh, et al., 2002).  Potential consensus
binding sites were identified (Table 4) and ChIP analysis was first attempted to
determine p53 occupancy of the potential sites.  The DNA fragments isolated
using ChIP in HCT116 cells as described above were PCR amplified using
primers specific for each putative consensus site.  For several of these sites, we
encountered difficulties in obtaining PCR conditions providing a specific product
on genomic input DNA.  However, PCR on one of the potential sites in the
MOAP1 promoter yielded specific and robust signal using genomic input.
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However, binding of p53 at this site could not be detected above background
levels at any of the time points (Figure 1A).  More experimentation is necessary
before conclusions can be made regarding MOAP1 and ZFP90 as candidate p53
or ΔNp63α target genes.
Discussion
The HEK ChIP library/yeast screen described herein was undertaken to
identify candidate p53 target genes.  Of the fragments pulled out of the library,
the majority contained a putative p53 consensus binding site matching the
canonical consensus site at 17 out of 20 bp or better.  The “match” of a target
gene consensus binding site to the ideal consensus binding site may affect the
affinity of p53 to that site.  Using chromatin immunoprecipitation, Kaeser and
Iggo (2004) observed a two-fold higher occupancy of the distal p21 consensus
binding site 1 (18/20 bp match to the consensus), than the proximal p21
consensus binding site 2 (12/20 bp match) by p53 transfected into H1299 cells.
The fact that the library fragments match well to the canonical consensus binding
site suggests that the library is identifying sites to which p53 has substantial
affinity.  Also, in vitro studies showed that p53 has higher affinity for consensus
binding sites of genes involved in cell cycle arrest and DNA repair than the
binding sites of genes implicated in apoptosis (Szak et al., 2001; Kaeser and
Iggo, 2002; Weinberg et al., 2005).  Reporter-based transcriptional assays in
yeast and mammalian cells revealed that p53 has higher transcriptional activity
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when activity was assayed on consensus binding sites from cell cycle arrest,
DNA repair, and death receptor apoptotic target genes versus sites from genes
involved in mitochondrial apoptosis (Qian et al., 2002). The DNA fragments in our
ChIP library were generated from HEKs treated with ADR for 6 h.  In other
studies with HEKs, we observed that cells underwent cell cycle arrest in
response to ADR treatment at 6 h and no signs of apoptosis were observed (see
Chapter IV).  Therefore, we would expect that the majority of the fragments
identified in our library would correspond to target genes that are involved in cell
cycle arrest or DNA repair.
Another interesting finding from our HEK library screen was that 20% of
fragments matched to the genome in areas of chromosomes where there were
no known or predicted genes within 20 kb of the fragment.  This suggests that as
the human genome continues to be sequenced and annotated more thoroughly,
perhaps genes will be discovered in these regions, and lead to the identification
of additional target genes of p53.  Another possibility is that p53 may be
regulating microRNAs in these regions of the genome.  MicroRNAs are a group
of regulatory RNAs that control gene expression by decreasing the stability and
translation of the messenger RNA of the target of the microRNA (Kent and
Mendell, 2006).  Current estimates predict that microRNAs account for
approximately 3% of all human genes, though many remain to be validated
(Cummins and Velculescu, 2006).  Regulation of microRNAs may be another
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mechanism by which p53 exerts its tumor suppressive functions (Kent and
Mendell, 2006).
To complement our library screening, we performed microarray analyses
as a way to identify genes that are direct targets of p53 regulation.  One caveat
to microarray studies is that the observed changes in gene expression in
response to p53 expression are not limited to primary targets of p53.  However,
the identification of secondary targets can be valuable in the identification and
understanding of pathways regulated by p53.  In addition, comparison to
published microarray data would help to eliminate some of the secondary targets.
One candidate target gene of particular interest is RRAD.  RRAD is an
example of a candidate target identified in our library screen that was also
upregulated by p53 in our microarray analyses.  One study found that RRAD
expression is often lost in invasive carcinoma of the breast and yet in a subset of
tumors that retain expression of RRAD there was a correlation with
characteristics of poor prognosis: increased tumor size, higher grade, and
greater nodal involvement (Tseng et al., 2001).  When RRAD was overexpressed
in the MDA-MB435 breast cancer cell line, it resulted in increased colony
formation in soft agar and increased tumor size when injected into nude mice
(Tseng et al., 2001).  Strikingly, when nm23 was co-expressed with RRAD in the
same experiments, the increased tumorigenicity was abrogated in both model
systems.  Recent studies have identified the RRAD locus to be aberrantly
methylated in malignant mesotheliomas (Suzuki et al., 2005), invasive cervical
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carcinomas (Sova et al., 2006), and prostate cancers (Suzuki et al., 2006).  As
these findings suggest conflicting roles of RRAD, further experimentation is
necessary to define and understand the role of RRAD in tumorigenesis.
In HCT116 colorectal cancer cells, p53 occupied the candidate consensus
binding site in the RRAD promoter constitutively in the absence of genotoxic
stress.  p53 occupancy at this candidate binding site increased after 2 and 8 h of
ADR treatment.  Our data are strongly suggestive that RRAD is a direct target
gene of p53.  In support of this notion, RRAD has also been identified in a recent
screen for novel p53 targets from HCT116 cells treated with 5-fluorouracil (5-FU)
utilizing ChIP coupled with paired-end ditag (PET) sequencing (Wei et al., 2006).
RRAD is also upregulated in H1299 lung carcinoma cells ectopically expressing
TAp73γ (Jennifer Rosenbluth, unpublished data).  p73 is a p53 family member
thought to have overlapping functions with p53 in the response to DNA damage.
p73 is able to activate target genes involved in cell cycle arrest, DNA repair, and
apoptosis that have been previously identified as p53 targets, or that function in a
similar manner to p53 targets (Harms et al., 2004).  Further investigation will be
necessary to determine if both p53 and p73 can regulate transcription of RRAD
as well as the functional implications of the regulation.  Interestingly, p73 is
overexpressed in breast cancer (Zaika et al., 1999; Dominguez et al., 2001;
Garcia et al., 2004).  For this reason, it would seem that RRAD is more likely a
p73 target gene that can be modulated by p53 in certain circumstances.  Given
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the low levels of p73 in HEKs, perhaps the regulation of RRAD by p53 is more
evident.
Many questions remain regarding the role of p63, another p53 family
member, in p53-mediated signaling.  Microarray analyses on HEKs ectopically
expressing ΔNp63α were performed in parallel with those on GFP- and p53-
expressing HEKs.  Of note, the number of genes upregulated by p53 (866) far
exceeded the number of genes downregulated by p53 (120).  In contrast, the
number of genes downregulated by ΔNp63α (620) far exceeded the number
upregulated by ΔNp63α (145).  These results are likely indicative of the prevalent
function of p53 and ΔNp63α as a transcriptional activator and repressor,
respectively.  Of particular interest was a subset of genes that were inversely
regulated by p53 and ΔNp63α.  Validation of two of these genes, MOAP-1 and
ZFP90, is currently in progress.  MOAP-1 is of interest because it plays a role in
apoptosis (Tan et al., 2001).  An important tumor suppressive function of p53 is
its ability to induce apoptosis, though many questions remain regarding the
mechanisms by which p53 initiates and potentiates this process (Fridman and
Lowe, 2003).  The role of ΔNp63α in p53-regulated apoptosis also remains to be
elucidated, though it can repress pro-apoptotic genes (Barbieri et al., 2005).
Identification of additional apoptotic target genes regulated by p53 or ΔNp63α,
such as candidate target gene MOAP-1, would help in the understanding of p53-
mediated apoptotic pathways.  Though very little information is known about
ZFP90 specifically, it remains an interesting  candidate target gene due to the
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presence of zinc-finger domains in the protein through which ZFP90 has the
potential ability to bind DNA or RNA.  Initial attempts using ChIP to determine
p53 occupancy of potential consensus binding sites in the MOAP-1 and ZFP90
genes have not been successful.  However, efforts at validating MOAP-1 and
ZFP90 as potential p53 or ΔNp63α candidate genes will continue in future
endeavors.  There are multiple potential p53 binding sites in both the MOAP-1
and ZFP90 genes.  ChIP will be utilized to determine p53 binding at other
potential sites.  Also, the PCR conditions for some of the potential binding sites
need to be troubleshot.  In general, ChIP library/yeast screens and microarray
studies have been useful in identifying candidate p53 consensus binding sites
and target genes, which will ultimately provide information in an attempt to
complete our understanding of p53-mediated tumor suppression.
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CHAPTER IV
P53 AND ΔNP63α DIFFERENTIALLY BIND AND REGULATE TARGET
GENES INVOLVED IN CELL CYCLE ARREST, DNA REPAIR, AND
APOPTOSIS
Introduction
p53 is a sequence specific transcription factor (El-Deiry et al., 1992) that
controls the transcription of many genes (El-Deiry, 1998; Tokino & Nakamura,
2000) in response to a variety of cellular stresses, often in a cell type specific
manner (Yu et al., 1999).  However, the mechanism by which p53 selectively
regulates its many target genes is still not well defined.  Many factors are
believed to contribute to the ability of p53 to differentially regulate target genes.
One such factor is the differential affinity of p53 for consensus DNA binding sites.
In vitro, p53 has a higher affinity for consensus binding sites of genes involved in
cell cycle arrest and DNA repair than the binding sites of genes implicated in
apoptosis (Kaeser & Iggo, 2002; Qian et al., 2002; Szak et al., 2001; Weinberg et
al., 2005).  The “match” of a target gene consensus binding site to the canonical
consensus binding site may affect the affinity of p53 to that site (Kaeser & Iggo,
2004).  Post-translational modifications of p53 are also thought to play a role in
the ability of p53 to selectively regulate target genes (Appella & Anderson, 2001;
Bode & Dong, 2004).  Another aspect that may dictate differential p53-mediated
transcription of target genes is the timing of p53 binding to regulatory regions and
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subsequent recruitment of the basal transcriptional machinery.  Espinosa et al.
recently showed that p53 is constitutively bound to both consensus binding sites
in the p21 promoter (Espinosa et al., 2003).  In addition, members of the basal
transcriptional machinery, including RNA polymerase II, have been shown to be
constitutively bound to the proximal promoters of p53 target genes involved in
cell cycle arrest and DNA repair, but not apoptosis (Espinosa et al., 2003).  The
generality of these findings is not established nor whether there is a direct
relationship between the constitutive binding of p53 to target gene consensus
binding sites and the presence of basal transcriptional machinery bound to the
proximal promoters of those target genes.
Occupancy of p53 consensus binding sites in target genes by other p53
family members, p63 and p73, may also play an important role, whether
cooperative or antagonistic, in p53-mediated signaling. ΔNp63α is the most
abundant, if not only, expressed p63 isoform at the protein level in many different
squamous epithelial cells and glandular tissues (Westfall & Pietenpol, 2004).
The ΔNp63α protein exhibits transcriptional repressor activity and can repress
transcription at various p53 target gene promoters (Westfall et al., 2003).
However, the relative occupancy of select target genes by each of the family
members after various forms of genotoxic stress in relation to other key
transcription factors, such as RNA polymerase II, has not been examined and
was a goal of the current study.
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Using chromatin immunoprecipitation, we examined the binding of p53
family members and an essential component of the basal transcriptional
machinery (RNA polymerase II) to p53 target genes involved in either cell cycle
arrest, DNA repair, or apoptosis in primary human epidermal keratinocytes
(HEKs).  We found that in general, p53 occupancy at consensus binding sites in
target genes increased after treatment with ADR and UV, and ΔNp63α
occupancy decreased under these conditions.  Further, we observed an inverse
regulation of a panel of previously identified p53 target genes by p53 and
ΔNp63α, consistent with the theory that ΔNp63α and p53 can play antagonistic
roles at various target genes.  These data provide insight to a potential role of
ΔNp63α in the p53-mediated response to genotoxic stress.
Results
Divergent Binding of p53 Family Members To Target Genes Involved In Cell
Cycle Arrest and DNA Repair
To investigate the role of p53 family members in the regulation of select
target genes, we sought to examine the occupancy of p53, p63, and p73 at
consensus binding sites in target gene regulatory regions using chromatin
immunoprecipitation (ChIP).  We used primary HEKs as our model system to
minimize genetic and epigenetic alterations frequently observed in established
cell lines.  Prior to performing ChIP, we verified expression levels of the proteins
under analysis and assessed the cellular response of HEKs to genotoxic agents.
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HEKs were treated with either ADR (0.5 mM) or UV (50 J/m2) for 2, 6, 12, and 24
h.  Western analysis was performed to determine pol II, p53, phospho-S15-p53
(P-S15-p53), ΔNp63α, and p73 protein levels. (Figure 2).  Control, untreated
HEKs constitutively expressed low levels of p53.  A continual increase in p53
levels was observed over the 2 to 24 h exposure to ADR.  Levels of p53
increased at 2 h after exposure to UV and remained elevated for the duration of
the timecourse.  Accumulation of p53 protein after ADR and UV treatment was
accompanied by a corresponding increase in p53 phosphorylation at S15.
Conversely, there was a decrement in the levels of the only detectable isoform of
p63 expressed in the primary cultures of the HEKs, ΔNp63α, after both ADR and
UV treatment.  Over the same time course, pol II protein remained unchanged
after either genotoxic treatment.  Of note, we were unable to detect expression of
any of the p73 protein isoforms in control or treated HEKs that were assayed in
parallel Western analyses with a p73-specific antibody.  This same antibody
generated a strong signal on protein lysates from H1299 cells ectopically
expressing the TAp73α or ΔNp73β isoforms (data not shown).  Further, we could
not detect appreciable levels of p73 protein after immunoprecipitation of 2 mg of
cell lysate followed by Western analysis (data not shown).  Since p73 protein was
not readily detectable in control or treated HEKs, we focused on p53 and
ΔNp63α.
We also examined p53 downstream signaling events by determining the
levels of p21 and MDM2 proteins, two key p53 targets (Figure 2).  Levels of p21
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and MDM2 increased in response to ADR and UV.  After treatment of the primary
HEKs with either ADR or UV radiation, we did not observe any gross changes in
viability of the cultures (data not shown).  To assess HEK viability after ADR or
UV radiation, we performed Western analyses for poly-ADP-ribose polymerase
(PARP) and determined if there was any PARP cleavage present in the treated
cells.  There were very low levels of PARP cleavage at 24 h of ADR treatment.
Thus, in these primary, untransformed cells, ADR and UV radiation stimulated
the p53 signaling pathway as evidenced by elevation of p21 and MDM2 without
concomitant induction of robust apoptosis.  Further, the observed inverse
regulation of p53 and ΔNp63α is relevant for interpretation of the following ChIP
analyses.
To analyze p53 and ΔNp63α occupancy at select target gene consensus
sites, rapidly growing HEKs were either untreated, or treated with ADR or UV as
described above.  After 2, 6, 12, or 24 h, the cells were formaldehyde-
crosslinked, and protein lysates were harvested.  To generate control templates
for PCR, identical plates of HEKs were harvested without formaldehyde-
crosslinking.  Crosslinked and non-crosslinked lysates were sonicated to shear
the chromatin and subjected to immunoprecipitation using p53 or p63 antibodies.
To control for non-specific binding, crosslinked lysates were also
immunoprecipitated using isotype-matched antibodies.  Initially we examined p53
target genes involved in growth arrest (p21 and 14-3-3σ) and DNA repair (p48
and p53R2).  Using the DNA fragments immunoprecipitated with p53- or p63-
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specific antibodies, PCR was employed to amplify regions of the p21 (El-Deiry et
al., 1993) and 14-3-3σ (Hermeking et al., 1997) promoters, p48 5’-UTR (Tan &
Chu, 2002), and p53R2 intron 1 (Tanaka et al., 2000) that contain p53 consensus
binding sites.  As a negative control, a region of the GAPDH promoter was
amplified from each set of immunoprecipitated DNA fragments and detectable
binding of p53 or ΔNp63α was not observed (data not shown).  Due to our
inability to readily detect p73 protein, we did not perform p73 ChIP analyses.
The ChIP analyses of p21, 14-3-3σ, p48, and p53R2 showed that both
p53 and ΔNp63α were bound constitutively, in the absence of genotoxic stress,
to the consensus binding sites of all genes examined (Figures 3, 4, 5, and 6,
“p53”, “ΔNp63α”).  After treatment with the genotoxic agents, an increase in p53
binding to all target gene consensus binding sites was observed.  We observed a
decrease in ΔNp63α binding accompanying the increase in p53 binding.
Post-translational modifications such as phosphorylation are known to
play important roles in p53 protein stability, DNA binding, and chromatin access
(Appella & Anderson, 2001; Bode & Dong, 2004).  Phosphorylation of p53 at S15
is one modification that occurs after genotoxic stress and is able to stimulate p53
transactivation (Dumaz and Meek, 1999) primarily by conferring enhanced
binding of p53 to CBP/p300 (Lambert et al., 1998).  We examined if the p53
bound, either constitutively or after genotoxic stress, was phosphorylated at S15.
We performed parallel ChIP experiments using a phospho-S15-p53 antibody to
immunoprecipitate P-S15-p53 out of crosslinked and non-crosslinked
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lysates.  Under conditions of rapid growth, P-S15-p53 was not detected at any of
the target gene consensus binding sites (Figures 3 through 6, “P-S15-p53”).  Two
to six hours after treatment with ADR or UV, binding of P-S15-p53 was
detectable at all binding sites.
In order to determine if there was a relationship between p53 and ΔNp63α
binding and the occupancy of select promoters by a component of the basal
transcriptional machinery, we examined the binding of pol II to target gene
proximal promoters.  We performed ChIP on the same templates as described
above using a pol II antibody to immunoprecipitate pol II from formaldehyde-
crosslinked and non-crosslinked lysates.  The resulting DNA fragments were
used as template for amplification of the proximal promoter region of each p53
target gene.  For these studies, the proximal promoter region was defined as the
region 50-100 bp up and downstream of the transcriptional start site.  In the
absence of genotoxic stress, pol II was constitutively bound to the proximal
promoters of p21 and 14-3-3σ, though no constitutive binding of pol II was
detected at the proximal promoters of p48 or p53R2 (Figures 3 through 6, “pol
II”).  After ADR treatment, binding of pol II was elevated, remained relatively
constant at the proximal promoters of p21, 14-3-3σ, and p53R2 and increased
over time at the p48 proximal promoter.  Similarly, after UV treatment, binding of
pol II was elevated and remained constant at the p21 and 14-3-3σ proximal
promoters; however, binding increased over time at both the p48 and p53R2
proximal promoters.  The lack of constitutive binding of pol II at the proximal
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promoters of p48 and p53R2 suggests that there is not a direct relationship
between constitutive binding of p53 or ΔNp63α and constitutive binding of pol II.
Rather, our data suggest there is a relationship between the location of the p53
consensus binding site in the target gene and constitutive binding of pol II.  p21
and 14-3-3σ contain consensus binding sites 5’ of the transcriptional start site
(El-Deiry et al., 1993; Hermeking et al., 1997).  Correspondingly, these genes
also have robust constitutive pol II binding at their proximal promoters (Figures 3
and 4, “pol II”).  In contrast, p48 and p53R2 have consensus binding sites
downstream of the transcriptional start site (Tan & Chu, 2002; Tanaka et al.,
2000) and we were not able to detect constitutive binding of pol II to their
proximal promoters (Figures 5 and 6, “pol II”).
To determine the relationship between p53, ΔNp63α, P-S15-p53, and pol
II binding to gene regulatory regions and gene expression, we isolated RNA from
HEKs in parallel with the ChIP experiments and examined expression of p21, 14-
3-3σ, p48, and p53R2 using quantitative real-time PCR.  We observed a
significant increase in p21 (ADR: 16-fold increase, UV: 12-fold increase), p48
(ADR: 2.7-fold increase, UV: 3.6-fold increase), and p53R2 (ADR: 19-fold
increase, UV: 6.1-fold increase) mRNA over the time courses of both ADR and
UV treatment (Figures 3, 5, and 6, bottom panels), whereas 14-3-3σ mRNA
levels stayed relatively constant (ADR: 1.6-fold increase, UV: 1.6-fold increase)
(Figure 4, bottom panel).  The general findings that emerged from the ChIP
binding and gene expression data were that in response to genotoxic stress,
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binding of p53 increased at the consensus binding sites of target genes under
study, as did P-S15-p53.  In fact the latter appeared to closely correlate with
significant increases in transcript levels.  Concomitantly, ΔNp63α occupancy at
the majority of target gene consensus binding sites decreased after treatment
with ADR and UV.  Corresponding to these changes in consensus binding site
occupancy there was a significant upregulation of mRNA levels of the target
gene over the time course of ADR and UV treatment, as observed for p21, p48,
and p53R2.  The exception was that similar ChIP binding trends were observed
at the 14-3-3σ consensus binding sites as at the other target gene consensus
binding sites, yet little change in 14-3-3σ mRNA expression occurred during the
time course (ADR: 1.6-fold increase, UV: 1.6-fold increase).  Of note, qRT-PCR
and Western analysis revealed high constitutive levels of 14-3-3σ mRNA and
protein, respectively (data not shown).  Thus, in primary HEKs, 14-3-3σ is
regulated by additional mechanisms that diminish any significant p53-mediated
increase after genotoxic stress.
Differential Constitutive Binding of p53 To Target Genes Involved in
Apoptosis
To investigate how p53 and its family members regulate target genes
involved in apoptosis we amplified regions of the Noxa promoter (Oda et al.,
2000) and Fas/APO1 intron 1 (Muller et al., 1998) that contain functional p53
consensus binding sites.  Constitutive binding of p53 was observed at the Noxa
consensus binding site, but not at the Fas/APO1 consensus binding site (Figures
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7 and 8, “p53”).  Increased binding of p53 to the binding sites in both genes was
observed following ADR and UV treatment.  In contrast, ΔNp63α bound to both
the Noxa and Fas/APO1 consensus binding sites constitutively; and its levels
decreased over the time course of ADR treatment and remained relatively
constant following UV treatment (Figures 7 and 8, “ΔNp63α”).  Phospho-S15-p53
binding increased at both the Noxa consensus binding site and the Fas/APO1
consensus binding site after treatment with ADR and UV (Figures 7 and 8, “P-
S15-p53”).  A low level of pol II was constitutively bound to the Noxa proximal
promoter, though pol II was not detected at the Fas/APO1 proximal promoter in
the absence of genotoxic stress (Figures 7 and 8, “pol II”).  Binding of pol II
increased at the Noxa and Fas/APO1 proximal promoters after ADR and UV
treatment.  Again, these data provide further evidence for a relationship between
the location of the p53 consensus binding site in the target gene and constitutive
binding of pol II as the binding sites of Noxa and Fas/APO1 are upstream and
downstream of the transcriptional start site, respectively.
When we examined mRNA levels of Noxa by quantitative real-time PCR,
there was a significant increase 2 h after ADR and UV treatment (Figure 7,
bottom panel) and the transcript remained elevated for the duration of the time
course.  A gradual increase in Fas/APO1 mRNA was observed in response to
both forms of genotoxic stress (Figure 8, bottom panel).  The more moderate
increase observed could be due to the absence of constitutively bound pol II.
Similar to our observations with the cell cycle arrest and DNA repair target
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genes, p53 and P-S15-p53 binding increased at both target gene consensus
binding sites after ADR and UV treatment.  Simultaneously, ΔNp63α occupancy
at the consensus binding sites generally decreased following exposure to ADR
and UV.  In addition, there were other significant differences in transcription
factor binding at the two apoptotic target gene regulatory regions that relate to
changes in mRNA expression.  For example, only a slight decrease in ΔNp63α
occupancy at the Fas/APO1 consensus binding site was observed following ADR
treatment and pol II constitutive binding was absent at the Fas/APO1 proximal
promoter.  We did not observe an increase in pol II binding until 2-6 h after
treatment with ADR, and Fas/APO1 mRNA levels increased gradually over the
time course (3.6-fold increase at 24 h).  In contrast, a more striking decrease in
ΔNp63α binding to the Noxa consensus binding site was observed after ADR
treatment.  Constitutive binding of pol II was present at the Noxa proximal
promoter, and a sharp increase in Noxa mRNA occurred by 2 h (4.7-fold increase
at 2 h) in response to both ADR.  As observed for the other set of genes above,
increases in P-S15-p53 binding to both the Noxa and Fas/APO1 consensus
binding sites correlated with the increases in mRNA for both target genes.
Inverse Regulation of Select Target Genes by p53 and ΔNp63α
In our ChIP analyses, we observed the constitutive binding of ΔNp63α to
p53 target genes involved in cell cycle arrest, DNA repair, and apoptosis and a
decrease in ΔNp63α occupancy after genotoxic stress at a majority of the sites
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examined.  These data, along with previous studies showing that ΔNp63α has
the ability to act as a transcriptional repressor (Bakkers et al., 2002; Westfall et
al., 2003; Barbieri et al., 2005; Barbieri et al., 2006) led us to investigate if p53
and ΔNp63α could coordinately regulate a broader range of gene targets.
Accordingly, we infected HEKs with adenoviruses expressing p53 or ΔNp63α.
We isolated mRNA 30 h post-infection as this was a time point at which we
observed a very robust expression of the majority of known targets.  Of note,
very little, if any, detectable apoptosis occurred in the HEKs infected with p53 or
ΔNp63α-expressing adenoviruses (data not shown).  Gene expression profiles
were obtained using the Affymetrix GeneChip and the expression levels of a
panel of p53 target genes are shown in Figure 9A.  Known p53 target genes
were upregulated after ectopic expression of p53 (Figure 9A, left side).  In
contrast, we observed a striking downregulation of a majority of these genes after
ectopic expression of ΔNp63α (Figure 9A, right side).  Of note, the target genes
examined have known roles in a number of p53-mediated signaling pathways,
including cell cycle arrest, DNA repair, and apoptosis.  The expression levels of a
subset of known p53 targets were quantitatively assayed using real-time PCR
(Figure 9B).  Although fold-changes varied, the inverse regulation of these genes
by p53 and ΔNp63α was readily apparent.
Of the genes shown in Figure 9B, the one showing the greatest degree of
upregulation by p53 and downregulation by ΔNp63α was MDM2, a negative
regulator of p53.  To gain some mechanistic insight to this regulation, we
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repeated the ChIP experiments described above to examine p53, ΔNp63α, and
P-S15-p53 binding to the known p53 consensus binding sites in the MDM2 gene
(Zauberman et al., 1995).  Only ΔNp63α bound constitutively to the MDM2
consensus binding sites (Figure 10).  Following ADR and UV treatment,
increased binding of p53 and P-S15-p53 was observed, as well as a
corresponding decrease in ΔNp63α  binding.  The ChIP binding patterns
observed for p53, ΔNp63α, and P-S15-p53 as well as the 14- and 15-fold
elevation in MDM2 mRNA expression in response to ADR and UV respectively,
exhibited the same trend as that seen with the cell cycle arrest, DNA repair, and
apoptotic target genes.  Pol II was not constitutively bound to the MDM2 proximal
promoter in the absence of genotoxic stress, though binding increased after both
ADR and UV treatment (Figure 10).  The p53 consensus binding sites in the
MDM2 gene are both located in intron 1 (Zauberman et al., 1995), and thus
similar to our observations with p48, p53R2, and Fas/APO1, we found that the
intronic location of a consensus binding site correlates with absence of
constitutive pol II binding to the proximal promoter region.
Discussion
The goal of this study was to provide further mechanistic insight to p53
family member regulation of target genes in response to genotoxic stress.  We
used primary HEKs as a model system to avoid genetic abnormalities present in
transformed cell lines and employed ChIP to examine occupancy of select target
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gene consensus binding sites by p53 family members.  Since p73 protein
expression was not readily detectable in control or treated HEKs (Figure 2), we
focused on p53 and ΔNp63α.
We observed constitutive binding of ΔNp63α to consensus binding sites in
target genes involved in cell cycle arrest, DNA repair, and apoptosis.  After
treatment with ADR or UV, a decrease in ΔNp63α occupancy was observed at
the majority of binding sites examined.  p53 was constitutively bound at all target
genes consensus binding sites, with the exception of the Fas/APO1 consensus
binding site.  Binding of p53 increased at all consensus binding sites after
treatment with ADR and UV.  Given the transcriptional repressor activity of
ΔNp63α  (Westfall et al., 2003; Barbieri et al., 2005; Barbieri et al., 2006),
constitutive binding of this protein to p53 target gene consensus binding sites
would allow for repression of genes involved in cell cycle arrest and apoptosis
and thus, allow cell viability and proliferation.  Coordinate binding of p53 would
allow for rapid induction of growth arrest and apoptosis with the onset of
regulatory events such as phosphorylation at S15 and decrement of ΔNp63α.
The loading of a promoter with a repressor and an activator allows for a rapid
switch type control when necessary or a gradual change.  Likely the difference
depends on the type of stress and the resulting post-translational modifications of
p53 and ΔNp63α.  ΔNp63α can modulate cell proliferation during development
through upregulation of the cyclin-dependent kinase inhibitor p57Kip2 (Beretta et
al., 2005).  It is believed that ΔNp63α exhibits this function of controlling cell
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proliferation during development in order to prevent aberrant expression of
p57Kip2, which can lead to developmental defects (Beretta et al., 2005).
In our ChIP analyses, we observed increased levels of P-S15-p53 at all
consensus binding sites 2 to 6 h following ADR or UV treatment.  When p53 is
phosphorylated on S15, p53 transactivation is stimulated (Dumaz and Meek,
1999).  Phosphorylation at S15 confers enhanced binding of p53 to CBP/p300
(Lambert et al., 1998).  Our data combined with previous observations (Espinosa
et al., 2003) suggests that this post-translational modification is a key regulatory
step in the upregulation of target gene expressions we observed following
genotoxic stress.  Colocalization of P-S15-p53 and p21 mRNA signal detected by
RNA-immuno fluorescence in situ hybridization was observed very early in the
response to damage indicating that P-S15-p53 targets p21 immediately in
response to stress, such as DNA damage (Espinosa et al., 2003).
We also examined the binding of pol II to the proximal promoters of select
p53 target genes to determine the relationship between p53 or ΔNp63α and pol II
binding to regulatory regions of target genes.  We observed constitutive pol II
binding to the p21, 14-3-3σ, and Noxa proximal promoters.   We conclude that
constitutive binding of p53 or ΔNp63α to target gene consensus binding sites
does not dictate the binding of pol II to target gene proximal promoters as
previously reported (Espinosa et al., 2003).  Rather, our results suggest that
there is a relationship between the location of the p53 consensus binding site in
the target gene and constitutive binding of pol II.  The target genes p21 (El-Deiry
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et al., 1993), 14-3-3σ (Hermeking et al., 1997), and Noxa (Oda et al., 2000) all
contain p53 consensus binding sites in the promoter region upstream of the
transcriptional start site.  Robust binding of pol II was observed at these proximal
promoter regions before and after treatment with ADR and UV.  The p53
consensus binding site for p48 is downstream of the transcriptional start site, in
the 5’-UTR region (Tan & Chu, 2002), and constitutive binding of pol II to the p48
proximal promoter was not discernable.  p53R2 (Muller et al., 1998), Fas/APO1
(Tanaka et al., 2000), and MDM2 (Zauberman et al., 1995) all contain intronic
p53 consensus binding sites; again, constitutive binding of pol II was not
detectable at the proximal promoters of these genes (Please see Table 5 for a
summary of these results).  Recent studies show that the positioning of
nucleosomes in eukaryotic genomes is dependent on the distribution of specific
sequences of DNA to which histones have higher affinity (Segal et al., 2006;
Ioshikhes, et al., 2006).  Perhaps the location of the p53 consensus binding site
can dictate nucleosome positioning and render chromatin more or less
accessible to large complexes of basal transcription factors, including pol II.
We also examined the corresponding mRNA expression of the genes
included in our ChIP analyses.  We saw consistent trends in the relationship
between promoter occupancy and regulation of transcript levels.  In response to
ADR and UV, increased binding of p53 and P-S15-p53 was observed at
consensus binding sites of genes involved in cell cycle arrest (p21, 14-3-3σ),
DNA repair (p48, p53R2), apoptosis (Noxa, Fas/APO1), and p53 negative
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regulation (MDM2).  Conversely, binding of ΔNp63α to consensus binding sites
of these genes decreased.  As these changes in promoter occupancy were
occurring, the transcript levels of each of these genes increased over the time
course of ADR and UV treatment, with the exception of 14-3-3σ, whose mRNA
levels remained constant in the absence and presence of ADR and UV.
However, there are constitutively high levels of 14-3-3σ mRNA and protein in
HEKs, indicating regulation of 14-3-3σ by factors in addition to p53.  The
absence of a relationship between the kinetics of p53 binding to target gene
regulatory regions and mRNA expression observed with 14-3-3σ is consistent
with previous findings (Szak et al., 2001).
Analysis of gene expression in HEKs ectopically-expressing p53 or
ΔNp63α revealed an inverse regulation of a panel of known p53 target genes that
have roles in cell cycle arrest, DNA repair, and apoptosis.  One target gene
inversely regulated by p53 and ΔNp63α in the microarray analysis was MDM2, a
negative regulator of p53.  We performed ChIP to determine the kinetics of
binding of p53 and ΔNp63α to the p53 consensus binding sites in MDM2 intron 1.
In HEKs, we found that ΔNp63α was bound to the MDM2 consensus binding
sites both constitutively in the absence of genotoxic stress and following
treatment with ADR and UV (though binding decreased after treatment).  In
contrast, using E1A-expressing mouse embryonic fibroblasts (MEFs), Flores et
al. (2002) did not detect constitutively bound p63 at the MDM2 consensus
binding sites, they only observed binding of p63 after 12 h of ADR treatment.
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This difference in p63 binding can be explained by the use of different model
systems in terms of species (mouse vs. human), tissue type (epithelial vs.
mesenchymal), and transformation status (primary, non-transformed vs. E1A-
expressing).  Repression of MDM2 by ΔNp63α adds another level of regulation to
the balance of MDM2 and p53 levels in unstressed cells.
Important to the understanding of p53-, p63-, and p73-mediated signaling
is deciphering the mechanisms and implications of coordinate regulation of target
genes by these transcription factors.  Target genes are emerging that are
commonly regulated by multiple p53 family members, or exhibit regulation by
only a single p53 family member (Harms et al., 2004; Ihrie et al., 2005; Sasaki et
al., 2005).  The ChIP and microarray analyses reported here support an
antagonistic role for ΔNp63α in the regulation of select p53 target genes in HEKs,
representing a physiologically relevant model system in which to study p53 and
ΔNp63α-mediated signaling.  Though its role as a p53-antagonist is supported by
results of the current study, as well as studies in primary mouse epidermal
keratinocytes in which ΔNp63α is acting as a dominant negative regulator of p53-
mediated apoptosis in response to UV-B treatment (Liefer et al., 2000), it is
clearly not the only role of p63.  For example, p63 has been demonstrated to
have an essential role in the development of epithelial structures and
maintenance of the epidermis both in humans and zebrafish (Koster and Roop,
2004).  Interestingly, in addition to p57Kip2 (as mentioned earlier), ΔNp63α can
transactivate select p53 target genes (Dohn et al., 2001).  The p53 family
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members can likely interact with a range of diverse components of the basal
transcription machinery and target gene expression is dictated by situation-
specific stimuli and availability of specific cofactors.  ΔNp63α may serve as a
cofactor for p53, and may be important for localization of protein complexes
involved in target gene discrimination.  Recently it was shown that p53 required
TAp63α in order to initiate apoptosis in neurons, exemplifying a setting in which
p53 acts as a p63 cofactor (Jacobs et al., 2005).  Identification of p63-associated
proteins will further clarify the role of p63 in the regulation of target genes.  As
additional target genes are discovered, it will be important to explore the
presence/absence of p53 family members at consensus binding sites under
physiologically relevant conditions.
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CHAPTER V
CONCLUSIONS
The p53 tumor suppressor protein is mutated in over 50% of all human
cancers (Vogelstein, 1990).  The majority of mutations in p53 are located in the
central core of the protein containing the DNA binding domain (Pavletich et al.,
1993).  p53 is a sequence-specific DNA binding protein (El-Deiry et al., 1992)
and directly activates transcription upon binding to DNA (Farmer et al., 1992).
Most importantly, p53 requires the sequence-specific transcriptional activity to
function as a tumor suppressor (Pietenpol et al., 1994).  Therefore, the proper
regulation of target genes involved in such processes as cell cycle arrest, DNA
repair, and apoptosis by p53 is of great importance in preventing tumorigenesis.
However, questions still remain regarding how p53 coordinately regulates all of
its target genes in response to genotoxic stress.
The purpose of the research presented in this dissertation was to provide
a greater understanding of the mechanisms of p53 select target gene activation
in response to genotoxic stress, specifically focusing on the role of the p53 family
member, ΔNp63α .  The first goal of my project was to identify novel p53
candidate target genes in primary HEKs.  We used ChIP/yeast screen
methodology followed by comparison to gene expression profiles generated by
microarray analyses of HEKs exogenously expressing p53 or ΔNp63α  to
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accomplish this goal.  The use of primary cells is of great value in that the
majority of screens to identify p53 target genes to date have been performed in
cancer cell lines. Our library screening and microarray experiments resulted in
the identification of many potential p53 candidate target genes.  The validation of
these candidates will yield knowledge of valuable target genes that both improve
our current understanding of p53 signaling pathways, but potentially identify
novel pathways in which p53 is involved.  Our microarray analyses also identified
a subset of target genes that are inversely regulated by p53 and ΔNp63α.  Most
of these have not been previously identified as p53 or ΔNp63α target genes.
This group of genes is of interest to us in that the observation of inverse
regulation aligns with our data discussed in Chapter IV.
Rationale for screening for novel p53 target genes is that the more p53
targets identified, the more complete our understanding regarding mechanisms
of p53-regulated tumor suppressive pathways.  For instance, analysis on a
greater number of target gene consensus binding sites may identify sequence-
specific patterns that dictate activation by p53.  Also, perhaps trends will emerge
regarding cell-type and stress-type specific responses mediated by p53.  p53
signaling pathways are complex, especially as new p53-mediated functions are
elucidated.  The continued identification of p53-regulated transcriptional targets
provides information with which to understand these pathways.
After mutation of the p53 gene, most often in the DNA binding domain, the
p53 protein can no longer engage its multitude of target genes to counteract
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genotoxic stress and prevent transformation.  Optimistically, each target gene of
p53 represents a potential therapeutic target for cancer treatment or prevention
due to its participation in p53 tumor suppression.  For example, introducing a
specific p53 target gene or a target gene peptide-mimetic to cancer cells could
potentially induce the outcome that p53 activation would otherwise achieve (i.e.
apoptosis) and could be a useful therapeutic strategy.  Better technologies
continue to be developed to specifically target cancer cells, which is essential for
such a strategy to be effective.
The second goal of my project was to identify factors involved in the
selective regulation of target genes by p53.  Again, using primary HEKs as a
model system we determined the constitutive binding status of p53, ΔNp63α, P-
S15-p53 and pol II to regulatory regions in p53 target genes involved in cell cycle
arrest, DNA repair, and apoptosis.  We then ascertained the changes in binding
that occurred after treatment with ADR and UV.
Prior to our ChIP experiments, we analyzed the response of HEKs to ADR
and UV.  We observed an increase in p53 and P-S15-p53, as well as an increase
in p53 target genes p21 and MDM2 after both ADR and UV treatment.  We
observed a decrease in ΔNp63α protein levels after both types of DNA damage,
consistent with previous studies in our lab (Westfall et al., 2005).  Upon treatment
with UV and paclitaxel, ΔNp63α protein levels decrease, accompanied by
changes in the phosphorylation status of ΔNp63α  and an increase in
ubiquitinated ΔNp63α (Westfall et al., 2005).  Further experimentation will be
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required to determine if the post-translational modifications of p53 and ΔNp63α
are coordinately regulated.
In our ChIP studies, we were interested in determining what transcription
factors were constitutively bound to regulatory regions in p53 target genes
involved in cell cycle arrest, DNA repair, apoptosis, and p53 negative regulation.
Though the levels of binding varied, we observed constitutive binding of p53 at all
target gene consensus binding sites except the Fas/APO1 consensus binding
site.  This lack of binding at the Fas/APO1 consensus binding site aligns with
previous studies determining that p53 has higher affinity for binding sites in target
genes involved in cell cycle arrest and DNA repair compared to binding sites in
genes involved in apoptosis (Szak et al., 2001; Kaeser and Iggo, 2002; Weinberg
et al., 2005).  However, we observe p53 constitutively bound at the Noxa
consensus binding site, which does not support of this theory.  Many more target
gene consensus binding sites need to be examined to definitely prove or
disprove this theory.
The “match” to the ideal consensus binding site is also thought to
influence the affinity of p53 to a target gene consensus binding site.  In our ChIP
studies, the match of the consensus binding site to the ideal consensus
sequence does not influence affinity as measured by constitutive binding.  We
observe ample constitutive binding of p53 to both consensus binding site in the
p21 promoter (consensus binding site 1 is an 18 out of 20 match; consensus
binding site 2 is a 12 out of 20 match).  In addition, we do not detect p53
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constitutive binding to the Fas/APO1 consensus binding site, which matches the
defined consensus at 18 out of 20 basepairs.  Again, more consensus binding
sites need to be analyzed to know definitely if this is a factor that can dictate p53
selective regulation of its target genes.
Our results show that the binding of p53 increases at all target gene
consensus binding sites after treatment with ADR and UV.  The level of P-S15-
p53 also increases at consensus binding sites in response to ADR and UV
treatment.  The phosphorylation of p53 S15 contributes to the disruption of the
interaction between p53 and MDM2 (Shieh et al., 1997) and also increases p53
binding to p300/CBP (Lambert et al., 1998).  Therefore, phosphorylation at p53
S15 results in increased stability and enhanced transcriptional activity of p53.  In
accordance with these properties, we observe accumulation of p53 (and P-S15-
p53) at the protein level after treatment with ADR and UV.  p53 (and P-S15-p53)
binding of target gene consensus binding sites increases after damage, and we
observe upregulation of the majority of target gene mRNA levels.
We were also interested in the binding of ΔNp63α to p53 target gene
consensus binding sites before and after genotoxic stress.  We detected
constitutive binding of ΔNp63α to p53 consensus binding sites of all the genes
we examined in the absence of stress.  Following treatment with ADR and UV,
we observed inverse trends in binding compared to p53: ΔNp63α binding
decreased at target gene promoters after genotoxic stress.  The binding
corresponds to the decrease in ΔNp63α protein levels after damage.  Overall, the
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following pattern emerges from our data.  After treatment with ADR and UV, p53
(and P-S15-p53) binding increases at target gene consensus binding sites, while
ΔNp63α binding decreases.  Correspondingly, an upregulation of target gene
mRNA occurs.
To extend these observations, we examined the transcript levels of a
panel of known p53 target genes in our microarrays in which p53 and ΔNp63α
were exogenously expressed.  Again, a clear trend emerged.  Upon expression
of p53, mRNA levels of known p53 target genes increase.  However, when
ΔNp63α is exogenously expressed, mRNA levels of the same target genes
decrease.  Our ChIP and microarray data provide further support of the role of
ΔNp63α as a transcriptional repressor.
Our results also add to the knowledge of the role of ΔNp63α in p53-
mediated signaling.  ΔNp63α may act as a constitutive repressor at p53 target
genes in order to prevent aberrant expression.  p53 may be constitutively bound
simultaneously, allowing for an expedient response to genotoxic stress.  ΔNp63α
is overexpressed in several squamous cell carcinomas (Hibi et al., 2000; Sniezek
et al., 2004), supporting the view of ΔNp63α as an oncogene.  Our data could
potentially support such a role for ΔNp63α in that overexpression of this protein
would lead to suppression of p53 target genes and likely enable the
transformation process (Barbieri et al., 2006).
Examination of the binding of a member of the basal transcription
machinery, pol II, to target gene proximal promoters yielded interesting results.
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We did not observe differences in constitutive binding of pol II to target gene
promoters classified on their involvement in cell cycle arrest, DNA repair, or
apoptosis.  Rather, the location of the p53 consensus binding site dictated the
constitutive binding of pol II.  We observed constitutive pol II occupancy of the
proximal promoters of p21, 14-3-3σ, and Noxa.  These three genes all contain
binding sites in their promoters, 5’ of the transcription start site.  Conversely,
constitutive binding of pol II was not observed p48, p53R2, Fas/APO1, or MDM2
proximal promoters.  The p53 binding site is located downstream of the
transcription start site (5’UTR or intron) for this group of genes.  Analysis of the
chromatin structure and histone acetylation status surrounding each of these
genes may provide insight to the general conformation (opened/closed) in that
particular region of the chromosome.  Further experimentation is necessary to
confirm this trend and understand the functional implications.  An important next
step will be determine whether pol II binding is observed at the proximal promoter
of a target gene with a p53 consensus binding site in the promoter region of the
gene in the absence of constitutive binding of p53.  We do observe constitutive
p53 binding without concurrent pol II constitutive binding, but only in target genes
with consensus binding sites 3’ of the transcription start site.  This experiment will
help to determine whether p53 constitutive binding is required for constitutive pol
II binding at target genes with binding sites 5’ of the transcription start site.  It is
possible that simply the presence of the p53 consensus binding site at a target
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gene promoter renders that region of chromatin more open and flexible to allow
pol II binding.
Thus, the dissertation research presented here has resulted in the
identification of a number of potential p53 and ΔNp63α candidate target genes.
Preliminary validation of RRAD strongly suggests that it is a novel p53-regulated
gene.   In addition, we have observed inverse regulation of a panel of p53 target
genes involved in cell cycle arrest, DNA repair, apoptosis, and p53 negative
regulation by p53 and ΔNp63α.  This inverse regulation corresponds to inverse
binding of p53 and ΔNp63α at p53 consensus binding sites, and upregulation of
target gene mRNA.  These results provide further understanding of the role of
ΔNp63α in p53-mediated signaling.  Overall, increased knowledge regarding
p53-mediated tumor suppression, whether it is the role of ΔNp63α  or the
understanding of RRAD as a target gene, ultimately brings us a small step closer
to a cure for cancer.
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